US5229272A
(en)
*
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
EP0368684B2
(de)
*
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5196510A
(en)
*
|
1988-12-29 |
1993-03-23 |
Cytogen Corporation |
Molecular recognition units
|
EP0376851A3
(de)
*
|
1988-12-29 |
1991-06-26 |
Cytogen Corporation |
Molekular-Erkennungseinheiten
|
US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
DE3909799A1
(de)
*
|
1989-03-24 |
1990-09-27 |
Behringwerke Ag |
Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
|
US5318897A
(en)
*
|
1989-04-25 |
1994-06-07 |
Igen, Inc. |
Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
|
US5658753A
(en)
*
|
1989-04-25 |
1997-08-19 |
Paul; Sudhir |
Catalytic antibody components
|
US5236836A
(en)
*
|
1989-04-25 |
1993-08-17 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US5599538A
(en)
*
|
1989-04-25 |
1997-02-04 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US6048717A
(en)
*
|
1989-04-25 |
2000-04-11 |
Igen International, Inc. |
Inhibitors of catalytic antibodies
|
US5602015A
(en)
*
|
1989-04-25 |
1997-02-11 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US5194585A
(en)
*
|
1989-04-25 |
1993-03-16 |
Igen, Inc. |
Inhibitors of catalytic antibodies
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6291159B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
CA2016841C
(en)
*
|
1989-05-16 |
1999-09-21 |
William D. Huse |
A method for producing polymers having a preselected activity
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US5231015A
(en)
*
|
1989-10-18 |
1993-07-27 |
Eastman Kodak Company |
Methods of extracting nucleic acids and pcr amplification without using a proteolytic enzyme
|
US6274324B1
(en)
|
1989-12-01 |
2001-08-14 |
Unilever Patent Holdings B.V. |
Specific binding reagent comprising a variable domain protein linked to a support or tracer
|
GB8928501D0
(en)
*
|
1989-12-18 |
1990-02-21 |
Unilever Plc |
Reagents
|
DE59109264D1
(de)
†
|
1990-02-01 |
2004-10-28 |
Dade Behring Marburg Gmbh |
Herstellung und Verwendung von Genbanken menschlicher Antikörper ("Human-Antikörper-Bibliotheken")
|
GB9021671D0
(en)
*
|
1990-10-05 |
1990-11-21 |
Unilever Plc |
Delivery of agents
|
US5427908A
(en)
*
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5723286A
(en)
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
GB9016299D0
(en)
*
|
1990-07-25 |
1990-09-12 |
Brien Caroline J O |
Binding substances
|
DE4033120A1
(de)
*
|
1990-10-18 |
1992-04-23 |
Boehringer Mannheim Gmbh |
Verfahren zur herstellung von chimaeren antikoerpern
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
AU1025692A
(en)
*
|
1991-02-06 |
1992-08-13 |
Ciba-Geigy Ag |
Novel chimeric antiidiotypic monoclonal antibodies
|
AU660981B2
(en)
*
|
1991-03-12 |
1995-07-13 |
Astellas Us Llc |
CD2-binding domain of lymphocyte function associated antigen 3
|
MX9203138A
(es)
*
|
1991-03-12 |
1992-09-01 |
Biogen Inc |
Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
|
EP1471142B1
(de)
|
1991-04-10 |
2008-11-19 |
The Scripps Research Institute |
Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Technology Ltd. |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
NL9101290A
(nl)
*
|
1991-07-23 |
1993-02-16 |
Stichting Rega V Z W |
Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
|
US6764681B2
(en)
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US5270170A
(en)
*
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5733731A
(en)
*
|
1991-10-16 |
1998-03-31 |
Affymax Technologies N.V. |
Peptide library and screening method
|
CA2124460C
(en)
*
|
1991-12-02 |
2007-08-28 |
Andrew David Griffiths |
Production of anti-self antibodies from segment repertoires and displayed on phage
|
ES2313867T3
(es)
*
|
1991-12-02 |
2009-03-16 |
Medical Research Council |
Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
|
DE4142077A1
(de)
*
|
1991-12-19 |
1993-06-24 |
Boehringer Mannheim Gmbh |
Verfahren zur expression rekombinanter antikoerper
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
US6399368B1
(en)
|
1992-01-17 |
2002-06-04 |
Board Of Regents, The University Of Texas System |
Secretion of T cell receptor fragments from recombinant Escherichia coli cells
|
HUT67943A
(en)
|
1992-02-06 |
1995-05-29 |
Schering Corp |
Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
CA2118508A1
(en)
*
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
GB9216983D0
(en)
*
|
1992-08-11 |
1992-09-23 |
Unilever Plc |
Polypeptide production
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
DE4233152A1
(de)
*
|
1992-10-02 |
1994-04-07 |
Behringwerke Ag |
Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
DK1231268T3
(da)
*
|
1994-01-31 |
2005-11-21 |
Univ Boston |
Polyklonale antistofbiblioteker
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US6056957A
(en)
*
|
1994-08-04 |
2000-05-02 |
Schering Corporation |
Humanized monoclonal antibodies against human interleukin-5
|
US6696248B1
(en)
|
1995-08-18 |
2004-02-24 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
ES2176484T3
(es)
*
|
1995-08-18 |
2002-12-01 |
Morphosys Ag |
Bancos de proteinas/(poli)peptidos.
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
DE69738254T2
(de)
|
1996-05-10 |
2008-08-14 |
Novozymes A/S |
Methode zur bereitstellung von dna sequenzen
|
DE69637484T2
(de)
|
1996-08-19 |
2010-06-24 |
Morphosys Ip Gmbh |
Vektoren/DNA-Sequenzen aus humanen kombinatorischen Antikörper-Bibliotheken
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
EP1027439B1
(de)
*
|
1997-10-27 |
2010-03-17 |
Bac Ip B.V. |
Multivalente antigenbindende proteine
|
AU2583899A
(en)
|
1998-02-04 |
1999-08-23 |
Invitrogen Corporation |
Microarrays and uses therefor
|
CA2328422A1
(en)
|
1998-05-13 |
1999-11-18 |
Diversys Limited |
Selection system
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US7534605B2
(en)
|
1999-06-08 |
2009-05-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
ES2349348T3
(es)
|
2000-01-27 |
2010-12-30 |
Medimmune, Llc |
Anticuerpos neutralizantes de rsv de ultra alta afinidad.
|
US8101553B1
(en)
|
2000-02-22 |
2012-01-24 |
Medical & Biological Laboratories Co., Ltd. |
Antibody library
|
CA2401652A1
(en)
|
2000-03-01 |
2001-09-07 |
Medimmune, Inc. |
High potency recombinant antibodies and method for producing them
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
AU2001253589B2
(en)
*
|
2000-04-17 |
2007-08-16 |
Dyax Corp |
Methods of constructing display libraries of genetic packages for members of a diverse family of peptides
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
CN1451043A
(zh)
|
2000-06-29 |
2003-10-22 |
艾博特公司 |
双特异性抗体及其制备方法和用途
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
CA2429544C
(en)
|
2000-11-17 |
2010-10-19 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6919189B2
(en)
|
2000-12-11 |
2005-07-19 |
Alexion Pharmaceuticals, Inc. |
Nested oligonucleotides containing a hairpin for nucleic acid amplification
|
EP3569610A3
(de)
|
2000-12-12 |
2020-03-18 |
Medlmmune, LLC |
Moleküle mit verlängerter halbwertzeit, zusammensetzungen und verwendungen dafür
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
US20030119056A1
(en)
|
2000-12-18 |
2003-06-26 |
Ladner Robert Charles |
Focused libraries of genetic packages
|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Rgmおよびそのモジュレーターの用途
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
US20030104402A1
(en)
*
|
2001-01-23 |
2003-06-05 |
University Of Rochester |
Methods of producing or identifying intrabodies in eukaryotic cells
|
EP2067486A1
(de)
|
2001-01-31 |
2009-06-10 |
Biogen Idec Inc. |
Verwendung von CD23 Antagonisten zur Behandlung von neoplastischen Erkrankungen
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
GB0115841D0
(en)
|
2001-06-28 |
2001-08-22 |
Medical Res Council |
Ligand
|
DK1399484T3
(da)
*
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
WO2004058821A2
(en)
*
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
CA2454618C
(en)
|
2001-07-24 |
2012-04-03 |
Biogen Idec Ma, Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
CA2457636C
(en)
|
2001-08-10 |
2012-01-03 |
Aberdeen University |
Antigen binding domains
|
WO2003018749A2
(en)
*
|
2001-08-22 |
2003-03-06 |
Shengfeng Li |
Compositions and methods for generating antigen-binding units
|
WO2003035842A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Dyax Corporation |
Hybridization control of sequence variation
|
US7175983B2
(en)
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
GB0126378D0
(en)
|
2001-11-02 |
2002-01-02 |
Oxford Biomedica Ltd |
Antigen
|
AU2002360068B2
(en)
*
|
2001-12-21 |
2009-09-03 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Method for cloning of variable domain sequences
|
EP2075256A2
(de)
|
2002-01-14 |
2009-07-01 |
William Herman |
Gezielte Liganden
|
DK2508596T3
(en)
|
2002-02-21 |
2015-10-19 |
Inst Virology |
MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
|
PL375041A1
(en)
|
2002-04-05 |
2005-11-14 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
US7135310B2
(en)
|
2002-04-24 |
2006-11-14 |
The Regents Of The University Of California |
Method to amplify variable sequences without imposing primer sequences
|
CA2485506C
(en)
|
2002-05-17 |
2012-02-28 |
Alligator Bioscience Ab |
A method for in vitro molecular evolution of protein function
|
EP2332989B1
(de)
|
2002-05-22 |
2015-04-01 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Immunoglobulinrahmen mit verbesserter Stabilität im intrazellulären Raum und Verfahren zu deren Identifizierung
|
AU2003239966B9
(en)
|
2002-06-03 |
2010-08-26 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
EP2366718A3
(de)
*
|
2002-06-28 |
2012-05-02 |
Domantis Limited |
Ligand
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
WO2004015425A1
(en)
|
2002-08-07 |
2004-02-19 |
Umc Utrecht Holding B.V. |
Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
ES2449578T3
(es)
*
|
2002-09-06 |
2014-03-20 |
Amgen Inc. |
Anticuerpo monoclonal anti-IL-1R1 humano terapéutico
|
CA2487206A1
(en)
|
2002-10-07 |
2004-04-15 |
Ludwig Institute Cancer Research |
P53 binding polypeptide
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
WO2004041862A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
GB0230201D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Retargeting
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
CA2512545C
(en)
|
2003-01-10 |
2015-06-30 |
Karen Silence |
Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
|
JP4538461B2
(ja)
*
|
2003-01-24 |
2010-09-08 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
ヒトIL−1βアンタゴニスト
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
GEP20094629B
(en)
|
2003-03-19 |
2009-03-10 |
Biogen Idec Inc |
Nogo receptor binding protein
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US20040248323A1
(en)
|
2003-06-09 |
2004-12-09 |
Protometrix, Inc. |
Methods for conducting assays for enzyme activity on protein microarrays
|
EP1498133A1
(de)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Verwendung von pak-Inhibitoren zur Behandlung von Gelenkerkrankungen
|
EP1664115A2
(de)
*
|
2003-08-01 |
2006-06-07 |
Genentech, Inc. |
Antikörper cdr polypeptid-sequenzen mit limitierter diversität
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
WO2005023993A2
(en)
*
|
2003-09-09 |
2005-03-17 |
Integrigen, Inc. |
Methods and compositions for generation of germline human antibody genes
|
AU2004275828B2
(en)
|
2003-09-23 |
2010-04-29 |
University Of North Carolina At Chapel Hill |
Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
|
PL1673450T3
(pl)
|
2003-10-14 |
2010-10-29 |
Baxalta Inc |
Polipeptyd przekształcający epoksyd witaminy K VKORC1, obiekt działania leczniczego kumaryny i jej pochodnych
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
AU2004295699A1
(en)
|
2003-12-01 |
2005-06-16 |
Dako Denmark A/S |
Methods and compositions for immuno-histochemical detection
|
GB0328690D0
(en)
|
2003-12-10 |
2004-01-14 |
Ludwig Inst Cancer Res |
Tumour suppressor protein
|
SG10201404273QA
(en)
|
2003-12-23 |
2014-10-30 |
Genentech Inc |
Novel anti-il 13 antibodies and uses thereof
|
WO2005069970A2
(en)
*
|
2004-01-20 |
2005-08-04 |
Kalobios, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
GB0406215D0
(en)
|
2004-03-19 |
2004-04-21 |
Procure Therapeutics Ltd |
Prostate stem cell
|
ATE515515T1
(de)
|
2004-03-30 |
2011-07-15 |
Glaxo Group Ltd |
Immunglobuline gegen menschlisches osm
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
US7662921B2
(en)
|
2004-05-07 |
2010-02-16 |
Astellas Us Llc |
Methods of treating viral disorders
|
EP2740743A3
(de)
|
2004-06-01 |
2015-08-19 |
Domantis Limited |
Bispezifische Fusions-Antikörper mit erhöhter Serumhalbwärtszeit
|
US7977071B2
(en)
|
2004-06-02 |
2011-07-12 |
Adalta Pty Ltd. |
Binding moieties based on shark ignar domains
|
RS52593B
(en)
|
2004-06-24 |
2013-04-30 |
Biogen Idec Ma Inc. |
TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
GB0414886D0
(en)
|
2004-07-02 |
2004-08-04 |
Neutec Pharma Plc |
Treatment of bacterial infections
|
EP1967529A1
(de)
|
2004-07-20 |
2008-09-10 |
Symphogen A/S |
Rekombinanter polyklonaler Anti-Rhesus-D-Antikörper und Herstellungsverfahren
|
JP4870667B2
(ja)
|
2004-07-20 |
2012-02-08 |
シムフォゲン・アクティーゼルスカブ |
組換えポリクローナルタンパク質またはポリクローナル細胞株を構造上特徴付ける方法
|
KR101422286B1
(ko)
|
2004-07-22 |
2014-07-23 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
결합 분자
|
GB0416487D0
(en)
|
2004-07-23 |
2004-08-25 |
Isis Innovation |
Modified virus
|
CA2576193A1
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
PL3540062T3
(pl)
*
|
2004-11-16 |
2021-12-27 |
Humanigen, Inc. |
Wymiana kasety dla regionu zmiennego immunoglobuliny
|
GB0425739D0
(en)
*
|
2004-11-23 |
2004-12-22 |
Procure Therapeutics Ltd |
Humanised baculovirus 2
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
EP1997890A1
(de)
|
2004-12-30 |
2008-12-03 |
Agency for Science, Technology and Research |
Für die Apoptose chinesischer Hamster spezifische Gene
|
EP1838736B1
(de)
|
2005-01-05 |
2013-03-06 |
Biogen Idec MA Inc. |
Cripto-bindende moleküle
|
ATE473446T1
(de)
|
2005-01-14 |
2010-07-15 |
Ablynx Nv |
Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
|
ATE541212T1
(de)
|
2005-03-11 |
2012-01-15 |
Sanofi Sa |
Verwendung von mgc4504
|
AU2005329450A1
(en)
|
2005-03-15 |
2006-09-28 |
University Of North Carolina At Chapel Hill |
Methods and compositions for producing active Vitamin K-dependent proteins
|
AU2006226192A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
WO2006105021A2
(en)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
EP1882044A1
(de)
|
2005-05-11 |
2008-01-30 |
sanofi-aventis |
Verwendung von gip gene promoter polymorphismus.
|
US8188223B2
(en)
|
2005-05-18 |
2012-05-29 |
Ablynx N.V. |
Serum albumin binding proteins
|
TW200716174A
(en)
|
2005-05-19 |
2007-05-01 |
Centocor Inc |
Anti-MCP-1 antibodies, compositions, methods and uses
|
HUE039846T2
(hu)
|
2005-05-20 |
2019-02-28 |
Ablynx Nv |
Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
|
JP5372500B2
(ja)
|
2005-06-17 |
2013-12-18 |
トレラクス リクイデーティング トラスト |
Ilt3結合分子およびその使用
|
CN103145842A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
CA2902070A1
(en)
|
2005-07-08 |
2007-01-18 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP1928506A4
(de)
|
2005-08-19 |
2009-10-21 |
Abbott Lab |
Doppel-variabel-domänen-immunglobulin und seine verwendungen
|
EP2500356A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
EP1931710B1
(de)
|
2005-08-31 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Konstruierte anti-il-23-antikörper
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
EP1937161B1
(de)
|
2005-10-03 |
2016-08-24 |
Smith and Nephew, Inc. |
Arretierende instrumentenanordnung
|
DE102005048898A1
(de)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
GB0521139D0
(en)
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
MX2008005405A
(es)
*
|
2005-10-28 |
2008-09-11 |
Florida Internat University Bo |
Anticuerpos quimericos equinos: humanos.
|
EP2510934A1
(de)
|
2005-11-04 |
2012-10-17 |
Biogen Idec MA Inc. |
Verfahren zur Förderung des Axon-Wachstums und des Überlebens dopaminergischer Neuronen
|
AU2006311803C1
(en)
|
2005-11-04 |
2015-05-14 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
EP1957531B1
(de)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP1957541A2
(de)
|
2005-11-21 |
2008-08-20 |
Laboratoires Serono SA |
Zusammensetzungen und verfahren zur herstellung von antigenbindenden hybridmolekülen und anwendungen davon
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
KR101434935B1
(ko)
|
2005-11-30 |
2014-10-01 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
|
US20090155283A1
(en)
*
|
2005-12-01 |
2009-06-18 |
Drew Philip D |
Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
|
JP2009518314A
(ja)
|
2005-12-02 |
2009-05-07 |
ジェネンテック・インコーポレーテッド |
Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
|
WO2007064882A2
(en)
|
2005-12-02 |
2007-06-07 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
RU2470941C2
(ru)
|
2005-12-02 |
2012-12-27 |
Дженентек, Инк. |
Связывающие полипептиды и их применения
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
BRPI0707276B1
(pt)
|
2006-01-27 |
2021-08-31 |
Biogen Ma Inc |
Polipeptídeo de fusão antagonista de receptor nogo
|
EP1987064A4
(de)
|
2006-02-01 |
2010-04-07 |
Arana Therapeutics Ltd |
Domänen-antikörper-konstrukt
|
EP2010677A4
(de)
|
2006-02-24 |
2010-04-14 |
Investigen Inc |
Verfahren und zusammensetzungen zum nachweis von polynukleotiden
|
ATE509033T1
(de)
|
2006-03-20 |
2011-05-15 |
Univ California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
US20100226920A1
(en)
*
|
2006-03-27 |
2010-09-09 |
Ablynx N.V. |
Medical delivery device for therapeutic proteins based on single domain antibodies
|
AU2007249408A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
CL2007001536A1
(es)
|
2006-05-30 |
2008-01-25 |
Genentech Inc |
Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
JP5597793B2
(ja)
|
2006-06-19 |
2014-10-01 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ilt3結合分子およびその使用
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
AU2007282023B2
(en)
*
|
2006-08-03 |
2012-09-13 |
Vaccinex, Inc. |
Anti-IL-6 monoclonal antibodies and uses thereof
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
CA2662350A1
(en)
|
2006-09-05 |
2008-03-13 |
Medarex, Inc. |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
EP3910065A1
(de)
|
2006-09-08 |
2021-11-17 |
AbbVie Bahamas Ltd. |
Interleukin-13-bindende proteine
|
ATE522625T1
(de)
|
2006-09-12 |
2011-09-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
SG178712A1
(en)
|
2006-10-02 |
2012-03-29 |
Medarex Inc |
Human antibodies that bind cxcr4 and uses thereof
|
GB0620705D0
(en)
|
2006-10-18 |
2006-11-29 |
Opsona Therapeutics |
Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
|
RU2483080C2
(ru)
|
2006-10-27 |
2013-05-27 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты и их применение
|
EP2102239B1
(de)
|
2006-11-30 |
2012-04-25 |
Research Development Foundation |
Verbesserte immunglobulin-bibliotheken
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2097097B1
(de)
|
2006-12-01 |
2018-05-30 |
E. R. Squibb & Sons, L.L.C. |
Antikörper, insbesondere menschliche antikörper, die an cd22 binden und deren verwendung
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
CA2672468A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
BRPI0720271A2
(pt)
|
2006-12-14 |
2014-01-28 |
Schering Corp |
Anticorpo anti-tslp projetado
|
JP5386364B2
(ja)
|
2006-12-18 |
2014-01-15 |
ジェネンテック, インコーポレイテッド |
抗Notch3アンタゴニスト抗体とNotch3関連疾患の予防及び治療におけるその使用
|
EP2115004A2
(de)
|
2006-12-19 |
2009-11-11 |
Ablynx N.V. |
Gegen gpcrs gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit gpcr in zusammenhang tehenden krankheiten und erkrankungen
|
US9156914B2
(en)
|
2006-12-19 |
2015-10-13 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
EA036660B1
(ru)
|
2007-01-09 |
2020-12-04 |
Байоджен Эмэй Инк. |
АНТИТЕЛО К Sp35 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ
|
NZ578065A
(en)
|
2007-01-16 |
2012-09-28 |
Abbott Lab |
Methods for treating psoriasis with an antibody which binds to an epitope
|
EP2111553B1
(de)
|
2007-01-24 |
2018-09-19 |
Carnegie Mellon University |
Optische biosensoren
|
WO2008103702A2
(en)
|
2007-02-23 |
2008-08-28 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
SG178804A1
(en)
|
2007-02-23 |
2012-03-29 |
Schering Corp |
Engineered anti-il-23p19 antibodies
|
PT2426144T
(pt)
|
2007-02-23 |
2019-02-06 |
Merck Sharp & Dohme |
Anticorpos anti-il-23p19 fabricados por engenharia genética
|
EP2447719B1
(de)
|
2007-02-26 |
2016-08-24 |
Oxford BioTherapeutics Ltd |
Proteine
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
WO2008104386A2
(en)
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
KR20100014568A
(ko)
|
2007-02-28 |
2010-02-10 |
쉐링 코포레이션 |
가공된 항-il-23r 항체
|
MX2009010492A
(es)
|
2007-03-30 |
2009-10-19 |
Abbott Lab |
Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
|
US9969797B2
(en)
|
2008-04-23 |
2018-05-15 |
Covalent Bioscience Incorporated |
Immunoglobulins directed to bacterial, viral and endogenous polypeptides
|
US20100143336A1
(en)
|
2007-04-26 |
2010-06-10 |
Opsona Therapeutics Limited |
Toll-like receptor binding epitope and compositions for binding thereto
|
EP3067368A1
(de)
|
2007-04-27 |
2016-09-14 |
Genentech, Inc. |
Starke, stabile und nicht immunsuppressive anti-cd4-antikörper
|
EP2155789B1
(de)
*
|
2007-05-01 |
2013-07-24 |
Research Development Foundation |
Immunglobulin-fc-bibliotheken
|
WO2008143666A2
(en)
|
2007-05-17 |
2008-11-27 |
Genentech, Inc. |
Crystal structures of neuropilin fragments and neuropilin-antibody complexes
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
GB0724331D0
(en)
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
CA2688433A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
EP2158219A2
(de)
*
|
2007-06-06 |
2010-03-03 |
Domantis Limited |
Polypeptide, variable antikörperdomänen und antagonisten
|
NO2631248T3
(de)
|
2007-06-15 |
2018-04-14 |
|
|
EP2171450B1
(de)
|
2007-06-22 |
2012-03-21 |
GENERA ISTRAZIVANJA d.o.o. |
Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen
|
US10214588B2
(en)
|
2007-07-03 |
2019-02-26 |
Ablynx N.V. |
Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
|
DK2175884T3
(en)
|
2007-07-12 |
2016-09-26 |
Gitr Inc |
Combination USING GITR BINDING MOLECULES
|
EP2023144A1
(de)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
|
JP5576275B2
(ja)
|
2007-08-03 |
2014-08-20 |
オプソナ セラピューティクス リミテッド |
再灌流障害および組織損傷を処置するためのtlr−2拮抗薬の使用
|
MX338395B
(es)
|
2007-08-29 |
2016-04-15 |
Sanofi Aventis |
Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
US8877688B2
(en)
*
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP3124497B1
(de)
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
|
WO2009036760A2
(en)
|
2007-09-18 |
2009-03-26 |
Dako Denmark A/S |
A rapid and sensitive method for detection of biological targets
|
KR102467302B1
(ko)
|
2007-09-26 |
2022-11-14 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
CA2700714C
(en)
|
2007-09-26 |
2018-09-11 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
HUE038588T2
(hu)
|
2007-11-07 |
2018-10-29 |
Genentech Inc |
IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra
|
WO2009067546A2
(en)
|
2007-11-19 |
2009-05-28 |
Celera Corpration |
Lung cancer markers and uses thereof
|
MX2010005324A
(es)
|
2007-11-19 |
2010-06-01 |
Genentech Inc |
Composiciones y metodos para inhibir el avance del tumor.
|
CN101952313B
(zh)
|
2007-11-27 |
2017-12-15 |
不列颠哥伦比亚大学 |
14‑3‑3η抗体及其用于诊断和治疗关节炎的用途
|
EP2215125A1
(de)
|
2007-11-27 |
2010-08-11 |
Ablynx N.V. |
Verfahren zur gewinnung von polypeptidkonstrukten mit zwei oder mehreren einzeldomänenantikörpern
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
US8426153B2
(en)
|
2007-12-03 |
2013-04-23 |
Carnegie Mellon University |
Linked peptides fluorogenic biosensors
|
DK2594590T3
(en)
|
2007-12-14 |
2015-01-12 |
Pfizer |
A process for the production of binding molecules to the human OX40-receptor
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
CN108864285A
(zh)
|
2008-01-03 |
2018-11-23 |
斯克里普斯研究院 |
通过模块识别结构域的抗体靶向
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2098536A1
(de)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
|
CA2717015A1
(en)
|
2008-03-05 |
2009-09-11 |
Ablynx Nv |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
NZ587765A
(en)
|
2008-03-18 |
2013-02-22 |
Abbott Lab |
Methods for treating psoriasis
|
EP2105742A1
(de)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Verwendung von Kathepsin-C
|
EP2604280A3
(de)
|
2008-03-27 |
2013-10-16 |
ZymoGenetics, Inc. |
Zusammensetzungen und Verfahren zur Hemmung von PDGFR-beta und VEGF-A
|
KR20100131003A
(ko)
*
|
2008-03-31 |
2010-12-14 |
제넨테크, 인크. |
천식을 치료 및 진단하기 위한 조성물 및 방법
|
JP2011516520A
(ja)
|
2008-04-07 |
2011-05-26 |
アブリンクス エン.ヴェー. |
Notch経路に指向性を有するアミノ酸配列及びその使用
|
AU2008201871A1
(en)
*
|
2008-04-16 |
2009-11-26 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Inhibition of angiogenesis and tumor metastasis
|
CA3049612C
(en)
|
2008-04-24 |
2023-01-10 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
SG157299A1
(en)
|
2008-05-09 |
2009-12-29 |
Agency Science Tech & Res |
Diagnosis and treatment of kawasaki disease
|
MY159667A
(en)
|
2008-05-09 |
2017-01-13 |
Abbvie Inc |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
RU2010151725A
(ru)
|
2008-05-16 |
2012-06-27 |
Аблинкс Нв (Be) |
Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
|
TW201006485A
(en)
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
AR072001A1
(es)
|
2008-06-03 |
2010-07-28 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
HUE042053T2
(hu)
|
2008-06-05 |
2019-06-28 |
Ablynx Nv |
Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
|
CN102316894A
(zh)
|
2008-06-20 |
2012-01-11 |
惠氏有限责任公司 |
来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
|
JP5674654B2
(ja)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
EP2982695B1
(de)
|
2008-07-09 |
2019-04-03 |
Biogen MA Inc. |
Zusammensetzungen mit antikörpern gegen lingo oder fragmenten davon
|
KR20110036638A
(ko)
|
2008-07-25 |
2011-04-07 |
리차드 더블유. 와그너 |
단백질 스크리닝 방법
|
US8795981B2
(en)
|
2008-08-08 |
2014-08-05 |
Molecular Devices, Llc |
Cell detection
|
US9580513B2
(en)
|
2008-08-08 |
2017-02-28 |
Agency For Science, Technology And Research (A*Star) |
VHZ for diagnosis and treatment of cancers
|
MY153074A
(en)
|
2008-08-14 |
2014-12-31 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-il-12/11-23 antibodies
|
AU2009288167B2
(en)
|
2008-09-03 |
2015-10-22 |
Genentech, Inc. |
Multispecific antibodies
|
CN102282172B
(zh)
|
2008-09-07 |
2014-02-19 |
台湾醣联生技医药股份有限公司 |
抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
|
EP2329261B1
(de)
|
2008-09-12 |
2014-06-18 |
Dako Denmark A/S |
Biomarker für prostatakrebs
|
US8417011B2
(en)
|
2008-09-18 |
2013-04-09 |
Molecular Devices (New Milton) Ltd. |
Colony detection
|
CA2744523A1
(en)
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of molecules and displayed molecules and collections
|
US20100081575A1
(en)
*
|
2008-09-22 |
2010-04-01 |
Robert Anthony Williamson |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
EP2334300B1
(de)
|
2008-09-24 |
2016-02-17 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Zusammensetzung und verfahren zur behandlung von vorzeitigen wehen
|
PT2334705T
(pt)
|
2008-09-26 |
2017-03-22 |
Ucb Biopharma Sprl |
Produtos biológicos
|
EP2352764B1
(de)
|
2008-10-14 |
2018-03-28 |
Ablynx N.V. |
Aminosäuresequencen die an humanes cd4 und cxcr4, ccr5, tlr4, alphav integrin, beta3-integrin,beta1-integrin, humanes alpha2-integrin, cd81, sr-bi, claudin-1, claudin-6 bzw. claudin-9 binden und den viruseintritt neutralisieren.
|
AU2009314311B2
(en)
|
2008-10-29 |
2013-01-10 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
JP5823867B2
(ja)
|
2008-10-29 |
2015-11-25 |
アブリンクス エン.ヴェー. |
単一ドメイン抗原結合分子の製剤
|
EP2356146A1
(de)
|
2008-11-07 |
2011-08-17 |
Fabrus Llc |
Anti-dll4-antikörper und anwendungen davon
|
US8858940B2
(en)
|
2008-12-10 |
2014-10-14 |
Ablynx N.V. |
Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
EP2370465B1
(de)
|
2008-12-19 |
2019-01-23 |
Ablynx N.V. |
Genetische immunisierung zur herstellung von immunoglobulinen gegen zell-assoziierte antigene wie p2x7, cxcr7 oder cxcr4
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
CA2748757A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US20120058131A1
(en)
|
2009-01-21 |
2012-03-08 |
Oxford Biotherapeutics Ltd |
Pta089 protein
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
WO2010087972A2
(en)
|
2009-01-29 |
2010-08-05 |
Abbott Laboratories |
Il-1 binding proteins
|
EP2219029A1
(de)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen
|
JP5906090B2
(ja)
|
2009-02-17 |
2016-04-20 |
コーネル・リサーチ・ファンデーション・インコーポレイテッドCornell Research Foundation, Incorporated |
癌の診断のための方法およびキットならびに治療価の推定
|
JP5721639B2
(ja)
|
2009-02-19 |
2015-05-20 |
ダコ・デンマーク・エー/エス |
分子標的の検出のための方法と化合物
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
ES2639026T3
(es)
|
2009-03-05 |
2017-10-25 |
Oxford Biotherapeutics Ltd. |
Anticuerpos totalmente humanos específicos para CADM1
|
WO2010100437A2
(en)
|
2009-03-05 |
2010-09-10 |
University Of Sheffield |
Production of protein
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
US8835610B2
(en)
|
2009-03-05 |
2014-09-16 |
Abbvie Inc. |
IL-17 binding proteins
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
CA2757931C
(en)
|
2009-04-07 |
2019-03-26 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
BRPI1013877A2
(pt)
|
2009-04-10 |
2017-08-15 |
Ablynx Nv |
Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
|
UA108201C2
(xx)
|
2009-04-20 |
2015-04-10 |
|
Антитіла, специфічні для кадгерину-17
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
DK2424889T3
(en)
|
2009-04-30 |
2015-11-02 |
Ablynx Nv |
Process for the preparation of domain antibodies
|
CA2762837C
(en)
*
|
2009-05-20 |
2021-08-03 |
Novimmune S.A. |
Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
|
KR101805202B1
(ko)
|
2009-05-29 |
2017-12-07 |
모르포시스 아게 |
집합 및 집합의 사용 방법
|
PL2438087T3
(pl)
|
2009-06-05 |
2017-10-31 |
Ablynx Nv |
Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
JP5683581B2
(ja)
*
|
2009-06-30 |
2015-03-11 |
リサーチ ディベロップメント ファウンデーション |
免疫グロブリンFcポリペプチド
|
SG176947A1
(en)
|
2009-07-03 |
2012-01-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
IE20090514A1
(en)
|
2009-07-06 |
2011-02-16 |
Opsona Therapeutics Ltd |
Humanised antibodies and uses therof
|
EP2451839B1
(de)
|
2009-07-10 |
2020-04-22 |
Ablynx N.V. |
Verfahren zur erzeugung variabler domänen
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
CN105131112A
(zh)
|
2009-08-29 |
2015-12-09 |
Abbvie公司 |
治疗用dll4结合蛋白
|
EP2293072A1
(de)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Verwendung von Kathepsin H
|
JP5715137B2
(ja)
|
2009-08-31 |
2015-05-07 |
アボット・ラボラトリーズAbbott Laboratories |
主要有害心イベントの予測のためのバイオマーカーおよびその使用
|
CA2772628A1
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
SI2805731T1
(sl)
|
2009-09-03 |
2019-02-28 |
Ablynx N.V. |
Stabilne formulacije polipeptidov in njihove uporabe
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
KR20140048229A
(ko)
|
2009-09-14 |
2014-04-23 |
애브비 인코포레이티드 |
건선을 치료하는 방법
|
AU2010291902A1
(en)
*
|
2009-09-14 |
2012-04-05 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
SG10201408401RA
(en)
|
2009-09-16 |
2015-01-29 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
CA2775959A1
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
EP2488186B1
(de)
|
2009-10-16 |
2017-05-24 |
National University of Singapore |
Antineoplastische verwendung von arteminantagonisten
|
CA2777411C
(en)
|
2009-10-20 |
2018-06-19 |
Dako Denmark A/S |
Immunochemical detection of single target entities
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
JO3437B1
(ar)
|
2009-10-30 |
2019-10-20 |
Esai R & D Man Co Ltd |
أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
AU2010315304B2
(en)
|
2009-11-04 |
2014-03-27 |
Merck Sharp & Dohme Llc |
Engineered anti-TSLP antibody
|
US20120316071A1
(en)
|
2009-11-04 |
2012-12-13 |
Vaughn Smider |
Methods for affinity maturation-based antibody optimization
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
CN102640001A
(zh)
|
2009-11-05 |
2012-08-15 |
诺瓦提斯公司 |
预测纤维化进展的生物标记物
|
EP2499491B1
(de)
|
2009-11-11 |
2015-04-01 |
Gentian AS |
Immunassay zur untersuchung von assoziierten analyten unterschiedlichen ursprungs
|
US9644022B2
(en)
|
2009-11-30 |
2017-05-09 |
Ablynx N.V. |
Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
EP3135302A1
(de)
|
2009-12-02 |
2017-03-01 |
Imaginab, Inc. |
J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
EP3309176A1
(de)
|
2009-12-14 |
2018-04-18 |
Ablynx N.V. |
Immunoglobulin variable einzeldomänen-antikörper gegen ox40l, konstrukte und therapeutische verwendung
|
MY159156A
(en)
|
2009-12-21 |
2016-12-15 |
Genentech Inc |
Antibody formulation
|
KR101961495B1
(ko)
|
2009-12-23 |
2019-03-22 |
아비펩 피티와이 리미티트 |
면역-컨쥬게이트 및 그 제조방법 2
|
ES2585350T3
(es)
|
2009-12-23 |
2016-10-05 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti Bv8 y usos de los mismos
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
TWI513466B
(zh)
|
2010-01-20 |
2015-12-21 |
Boehringer Ingelheim Int |
抗凝血劑解毒劑
|
SG182590A1
(en)
|
2010-01-28 |
2012-08-30 |
Glaxo Group Ltd |
Cd127 binding proteins
|
EP2354159A1
(de)
|
2010-02-05 |
2011-08-10 |
RWTH Aachen |
CCL17-Inhibitoren zur Verwendung bei von T-Helferzellen gesteuerten Erkrankungen
|
WO2011098449A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
SI2533761T1
(sl)
|
2010-02-11 |
2019-08-30 |
Ablynx N.V. |
Postopki in sestavki za pripravo aerosolov
|
EP2536748B1
(de)
|
2010-02-18 |
2014-08-20 |
Genentech, Inc. |
Neuregulin-antagonisten und ihre verwendung zur behandlung von krebs
|
RU2605928C2
(ru)
|
2010-03-02 |
2016-12-27 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
SG10201504808XA
(en)
|
2010-03-17 |
2015-07-30 |
Abbott Res Bv |
Anti-Nerve Growth Factor (NGF) Antibody Compositions
|
NZ602040A
(en)
|
2010-03-24 |
2014-12-24 |
Genentech Inc |
Anti-lrp6 antibodies
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
EP2552962B1
(de)
|
2010-03-26 |
2016-03-23 |
Ablynx N.V. |
Einzelne, gegen cxcr7 gerichtete variable immunoglobulindomänen
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
EP3345926B1
(de)
|
2010-05-06 |
2023-04-05 |
Novartis AG |
Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
AU2011252883B2
(en)
|
2010-05-14 |
2015-09-10 |
Abbvie Inc. |
IL-1 binding proteins
|
RU2012149227A
(ru)
|
2010-05-20 |
2014-06-27 |
Аблинкс Нв |
Биологические материалы, относящиеся к her3
|
WO2011150079A1
(en)
|
2010-05-25 |
2011-12-01 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
BR112012029866A2
(pt)
|
2010-06-03 |
2017-03-07 |
Genentech Inc |
método para a determinação da presença de uma proteína steap-1
|
WO2011161545A2
(en)
|
2010-06-04 |
2011-12-29 |
The Netherlands Cancer Institute |
Non-hydrolyzable protein conjugates, methods and compositions related thereto
|
WO2011158019A1
(en)
|
2010-06-16 |
2011-12-22 |
Adjuvantix Limited |
Polypeptide vaccine
|
KR101885388B1
(ko)
|
2010-06-18 |
2018-08-03 |
제넨테크, 인크. |
항-Axl 항체 및 사용 방법
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
WO2012006503A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
KR20140002601A
(ko)
|
2010-07-09 |
2014-01-08 |
바이오겐 이데크 헤모필리아 인코포레이티드 |
키메라 응고 인자
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
CA3086837C
(en)
|
2010-07-16 |
2023-03-07 |
Adimab, Llc |
Libraries comprising segmental pools, and methods for their preparation and use
|
CN103108886B
(zh)
|
2010-07-20 |
2016-08-24 |
赛法隆澳大利亚控股有限公司 |
抗il-23杂二聚体特异性抗体
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
CN103209709A
(zh)
|
2010-08-05 |
2013-07-17 |
弗·哈夫曼-拉罗切有限公司 |
抗mhc抗体抗病毒性细胞因子融合蛋白
|
EP2603526A1
(de)
|
2010-08-13 |
2013-06-19 |
Medimmune Limited |
Monomere polypeptide mit abweichenden fc-regionen und verwendungsverfahren
|
CA2806021C
(en)
|
2010-08-13 |
2019-05-21 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
BR112013002444A2
(pt)
|
2010-08-13 |
2016-05-24 |
Roche Glycart Ag |
anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
|
EP2603524A1
(de)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta-bindende proteine
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
US9505829B2
(en)
|
2010-08-19 |
2016-11-29 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
CN103080134B
(zh)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
TW201215405A
(en)
|
2010-08-25 |
2012-04-16 |
Hoffmann La Roche |
Antibodies against IL-18R1 and uses thereof
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
CA3109036C
(en)
|
2010-08-31 |
2023-08-01 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
ES2641916T3
(es)
|
2010-08-31 |
2017-11-14 |
Genentech, Inc. |
Biomarcadores y métodos de tratamiento
|
CN103201293B
(zh)
|
2010-09-08 |
2016-04-27 |
哈洛齐梅公司 |
评估和鉴定或发展条件活性治疗蛋白的方法
|
RU2710717C2
(ru)
|
2010-09-09 |
2020-01-10 |
Пфайзер Инк. |
Молекулы, связывающиеся с 4-1ВВ
|
WO2012038744A2
(en)
|
2010-09-22 |
2012-03-29 |
Genome Research Limited |
Detecting mutations
|
US8497138B2
(en)
|
2010-09-30 |
2013-07-30 |
Genetix Limited |
Method for cell selection
|
GB201016494D0
(en)
|
2010-09-30 |
2010-11-17 |
Queen Mary Innovation Ltd |
Polypeptide
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
PL3279214T3
(pl)
|
2010-10-29 |
2025-03-24 |
Ablynx Nv |
Sposób wytwarzania pojedynczych domen zmiennych immunoglobuliny
|
CN108341868B
(zh)
|
2010-11-05 |
2022-06-07 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
WO2012062318A1
(en)
|
2010-11-08 |
2012-05-18 |
Dako Denmark A/S |
Quantification of single target molecules in histological samples
|
BR112013011003B1
(pt)
|
2010-11-08 |
2021-12-07 |
Novartis Ag |
Polipeptídeo e seus usos, célula hospedeira transgênica de microrganismo, nanocorpo monovalente, bivalente, multivalente, biparatópico ou multiparatópico, e composição farmacêutica
|
PE20140238A1
(es)
|
2010-11-10 |
2014-03-07 |
Genentech Inc |
Metodos y composiciones para inmunoterapia para enfermedad neural
|
NZ609707A
(en)
|
2010-11-19 |
2014-12-24 |
Morphosys Ag |
A collection and methods for its use
|
CN103328979B
(zh)
|
2010-12-06 |
2015-10-07 |
丹麦达科有限公司 |
组合的组织学染色
|
AR084342A1
(es)
|
2010-12-16 |
2013-05-08 |
Genentech Inc |
Diagnostico y tratamientos relacionados con la inhibicion de th2
|
TW201238973A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
JP6253987B2
(ja)
|
2010-12-20 |
2017-12-27 |
ジェネンテック, インコーポレイテッド |
抗メソテリン抗体及びイムノコンジュゲート
|
SG10201604699VA
(en)
|
2010-12-21 |
2016-07-28 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
EP2655607A4
(de)
|
2010-12-21 |
2014-05-14 |
Univ North Carolina |
Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
|
EA201390929A1
(ru)
|
2010-12-22 |
2013-12-30 |
Дженентек, Инк. |
Антитела к pcsk9 и способы их применения
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
JP5913363B2
(ja)
|
2010-12-23 |
2016-04-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二価結合剤によるポリペプチド二量体の検出
|
EP2655414B1
(de)
|
2010-12-23 |
2018-08-29 |
Roche Diagniostics GmbH |
Bispezifisches bindungsmolekül
|
CN103384825B
(zh)
|
2010-12-23 |
2017-05-24 |
霍夫曼-拉罗奇有限公司 |
通过二价结合剂检测经翻译后修饰的多肽
|
EP2471554A1
(de)
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel
|
WO2012092323A1
(en)
|
2010-12-28 |
2012-07-05 |
Xoma Technology Ltd. |
Cell surface display using pdz domains
|
WO2012109133A1
(en)
|
2011-02-07 |
2012-08-16 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides
|
KR20130118941A
(ko)
|
2011-02-10 |
2013-10-30 |
로슈 글리카트 아게 |
면역치료법
|
WO2012109624A2
(en)
|
2011-02-11 |
2012-08-16 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
EP2686016B1
(de)
|
2011-03-14 |
2019-05-01 |
Cellmid Limited |
Antikörper zur erkennung der n-domäne von midkin
|
WO2012125775A1
(en)
|
2011-03-16 |
2012-09-20 |
Sanofi |
Uses of a dual v region antibody-like protein
|
CN103917560B
(zh)
|
2011-03-28 |
2017-05-24 |
埃博灵克斯股份有限公司 |
双特异性抗‑cxcr7免疫球蛋白单可变结构域
|
ES2688591T3
(es)
|
2011-03-28 |
2018-11-05 |
Ablynx N.V. |
Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
BR112013025031A2
(pt)
|
2011-03-30 |
2017-08-01 |
Boehringer Ingelheim Int |
antídotos anticoagulantes
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
EP2511293A1
(de)
|
2011-04-13 |
2012-10-17 |
LEK Pharmaceuticals d.d. |
Verfahren zur Steuerung der Hauptkomplex-N-Glycan-Strukturen und der sauren Varianten und Variabilität in Bioprozessen, die rekombinante Proteine produzieren
|
WO2012143010A1
(en)
|
2011-04-19 |
2012-10-26 |
Dako Denmark A/S |
New method for enzyme-mediated signal amplification
|
KR20140031217A
(ko)
|
2011-04-20 |
2014-03-12 |
로슈 글리카트 아게 |
혈액-뇌 차단벽의 pH 의존적 통과를 위한 방법 및 구축물
|
WO2012142662A1
(en)
|
2011-04-21 |
2012-10-26 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
EP2518157A1
(de)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
EP2705056B1
(de)
|
2011-05-06 |
2018-11-14 |
Nexvet Australia Pty Ltd |
Anti-nervenwachstumsfaktor-antikörper und verfahren zu ihrer herstellung und verwendung
|
BR112013028655B1
(pt)
|
2011-05-06 |
2022-08-16 |
Zoetis Services Llc |
Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos
|
GB201114858D0
(en)
|
2011-08-29 |
2011-10-12 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of using the same
|
EP4026845A1
(de)
|
2011-05-06 |
2022-07-13 |
Zoetis Services LLC |
Antikörper gegen nervenwachstumsfaktor und verfahren zur herstellung und verwendung davon
|
CA2835094C
(en)
|
2011-05-06 |
2020-12-22 |
David Gearing |
Anti-nerve growth factor antibodies and methods of preparing and using the same
|
EP2707382B1
(de)
|
2011-05-09 |
2019-07-17 |
Ablynx NV |
Verfahren zur herstellung von variablen immunglobulin-einzeldomänen
|
EP2707723B1
(de)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Lc-ms/ms-verfahren mit mehrfachreaktionsüberwachung zur erkennung therapeutischer antikörper in tierischen proben mittels rahmensignaturpeptiden
|
EP2710035B1
(de)
|
2011-05-16 |
2017-04-12 |
F. Hoffmann-La Roche AG |
Fgfr1-agonisten und anwendungsverfahren
|
CN112225798B
(zh)
|
2011-05-17 |
2023-07-18 |
洛克菲勒大学 |
人类免疫缺陷病毒中和抗体及其使用方法
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
AU2012264809B2
(en)
|
2011-05-27 |
2017-05-04 |
Ablynx Nv |
Inhibition of bone resorption with RANKL binding peptides
|
WO2012166906A1
(en)
|
2011-05-31 |
2012-12-06 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
DK2718320T3
(en)
|
2011-06-10 |
2018-03-26 |
Medimmune Ltd |
ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
|
AU2012269720B2
(en)
|
2011-06-13 |
2015-01-22 |
Csl Limited |
Antibodies against G-CSFR and uses thereof
|
US8623666B2
(en)
|
2011-06-15 |
2014-01-07 |
Hoffmann-La Roche Inc. |
Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
|
EP2537532A1
(de)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
|
EP4350345A3
(de)
|
2011-06-23 |
2024-07-24 |
Ablynx N.V. |
Verfahren zur vorhersage, erkennung und reduzierung von aspezifischer proteininterferenz in tests mit variablen immunglobulin-einzeldomänen
|
IN2014CN00373A
(de)
|
2011-06-23 |
2015-04-03 |
Ablynx Nv |
|
IN2014CN00437A
(de)
|
2011-06-23 |
2015-04-03 |
Ablynx Nv |
|
RS55775B2
(sr)
|
2011-06-23 |
2022-10-31 |
Ablynx Nv |
Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
|
RS55716B1
(sr)
|
2011-06-28 |
2017-07-31 |
Oxford Biotherapeutics Ltd |
Terapeutski i dijagnostički cilj
|
SG10201605323SA
(en)
|
2011-06-28 |
2016-08-30 |
Oxford Biotherapeutics Ltd |
Antibodies to adp-ribosyl cyclase 2
|
TW201306866A
(zh)
|
2011-06-30 |
2013-02-16 |
Genentech Inc |
抗-c-met抗體調配物
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
CA2844141A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
CA2844538C
(en)
|
2011-08-23 |
2020-09-22 |
Roche Glycart Ag |
Bispecific antigen binding molecules
|
AR087608A1
(es)
|
2011-08-23 |
2014-04-03 |
Roche Glycart Ag |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
EP2751139A1
(de)
|
2011-08-30 |
2014-07-09 |
NVIP Pty Ltd |
Caninisierte tumornekrosefaktor-antikörper und verfahren zu ihrer verwendung
|
ES2908046T3
(es)
|
2011-09-09 |
2022-04-27 |
Medimmune Ltd |
Anticuerpos anti-siglec-15 y usos de los mismos.
|
SG2014010383A
(en)
|
2011-09-14 |
2014-07-30 |
Abeterno Ltd |
Intracellular cell selection
|
EP2756300A1
(de)
|
2011-09-15 |
2014-07-23 |
F.Hoffmann-La Roche Ag |
Verfahren zur förderung der differenzierung
|
GB201116116D0
(en)
|
2011-09-19 |
2011-11-02 |
Univ York |
Cell differentiation
|
MX391157B
(es)
|
2011-09-19 |
2025-03-21 |
Axon Neuroscience Se |
Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer.
|
MX2014002990A
(es)
|
2011-09-19 |
2014-05-21 |
Genentech Inc |
Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
|
SG10201800158XA
(en)
|
2011-09-22 |
2018-02-27 |
Amgen Inc |
Cd27l antigen binding proteins
|
US10138302B2
(en)
|
2011-09-23 |
2018-11-27 |
Ablynx N.V. |
Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
|
GB201116702D0
(en)
|
2011-09-28 |
2011-11-09 |
Procure Therapeutics Ltd |
Cell surface markers
|
EP2760889A4
(de)
|
2011-09-30 |
2015-04-15 |
Teva Pharmaceuticals Australia Pty Ltd |
Antikörper gegen tl1a und ihre verwendung
|
SG11201401287SA
(en)
|
2011-10-05 |
2014-05-29 |
Genentech Inc |
Methods of treating liver conditions using notch2 antagonists
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
CN108373506A
(zh)
|
2011-10-14 |
2018-08-07 |
霍夫曼-拉罗奇有限公司 |
抗HtrA1抗体及使用方法
|
CA2850836A1
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
RS20140202A1
(en)
|
2011-10-24 |
2014-10-31 |
Abbvie Inc. |
BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17
|
WO2013063095A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
AR088512A1
(es)
|
2011-10-24 |
2014-06-18 |
Abbvie Inc |
Anticuerpos dirigidos contra el tnf
|
GB201118359D0
(en)
|
2011-10-25 |
2011-12-07 |
Univ Sheffield |
Pulmonary hypertension
|
AU2012328980A1
(en)
|
2011-10-28 |
2014-04-24 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
EA201700111A1
(ru)
|
2011-10-28 |
2018-02-28 |
Тева Фармасьютикал Австралия Пти Лтд |
Полипептидные конструкции и их применение
|
CA2852709A1
(en)
|
2011-10-28 |
2013-05-02 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
GB201118840D0
(en)
|
2011-11-01 |
2011-12-14 |
Univ Sheffield |
Pulmonary hypertension II
|
US8883735B2
(en)
|
2011-11-04 |
2014-11-11 |
Novartis Ag |
Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
|
CN109897103B
(zh)
|
2011-11-04 |
2024-05-17 |
酵活英属哥伦比亚有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
DK2776466T3
(da)
|
2011-11-11 |
2017-11-20 |
Ucb Biopharma Sprl |
Albuminbindende antistoffer og bindingsfragmenter deraf
|
TW201326193A
(zh)
|
2011-11-21 |
2013-07-01 |
Genentech Inc |
抗-c-met抗體之純化
|
AU2012345926A1
(en)
|
2011-11-29 |
2014-05-29 |
Genentech, Inc. |
Compositions and methods for prostate cancer analysis
|
WO2013080050A2
(en)
|
2011-11-30 |
2013-06-06 |
Universitaetsklinikum Erlangen |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
UY34486A
(es)
|
2011-12-05 |
2013-07-31 |
Novartis Ag |
Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
|
KR102151383B1
(ko)
|
2011-12-05 |
2020-09-03 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
EP2788024A1
(de)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antikörper-formulierung
|
SG10201900915WA
(en)
|
2011-12-22 |
2019-03-28 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
RU2756106C2
(ru)
|
2011-12-22 |
2021-09-28 |
Ф. Хоффманн-Ля Рош Аг |
Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
UY34558A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
EA201491346A1
(ru)
|
2012-01-10 |
2014-11-28 |
Байоджен Айдек Ма Инк. |
Усиление транспорта терапевтических молекул через гематоэнцефалический барьер
|
BR112014017518A2
(pt)
|
2012-01-18 |
2018-09-04 |
Genentech Inc |
anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
|
RU2014133547A
(ru)
|
2012-01-18 |
2016-03-10 |
Дженентек, Инк. |
Способы применения модуляторов fgf19
|
CN107880124B
(zh)
|
2012-01-27 |
2021-08-13 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗与神经突变性相关的疾病的组合物和方法
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
MX366804B
(es)
|
2012-02-11 |
2019-07-25 |
Genentech Inc |
Translocaciones de la r-espondina y sus metodos de uso.
|
JP6152120B2
(ja)
|
2012-02-15 |
2017-06-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc受容体に基づくアフィニティークロマトグラフィー
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203587D0
(en)
|
2012-03-01 |
2012-04-11 |
Univ Warwick |
Modified bacterial cell
|
CA2860369A1
(en)
|
2012-03-02 |
2013-09-06 |
Roche Glycart Ag |
Predicitive biomarker for cancer treatment with adcc enhanced antibodies
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
ES2678211T3
(es)
|
2012-03-27 |
2018-08-09 |
Ventana Medical Systems, Inc. |
Conjugados de señalización y procedimientos de uso
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
EP2844300B1
(de)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17-antikörper und immunkonjugate
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
ES2843054T3
(es)
|
2012-05-10 |
2021-07-15 |
Zymeworks Inc |
Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
CA2873623C
(en)
|
2012-05-14 |
2021-11-09 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
EP2666786A1
(de)
|
2012-05-21 |
2013-11-27 |
PAION Deutschland GmbH |
Immuntherapie für intrakraniale Blutungen
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
KR101937733B1
(ko)
|
2012-05-24 |
2019-01-11 |
마운트게이트 그룹 리미티드 |
광견병 감염의 방지 및 치료에 관한 조성물 및 방법
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
CN104364266A
(zh)
|
2012-06-15 |
2015-02-18 |
霍夫曼-拉罗奇有限公司 |
抗-pcsk9抗体,制剂,剂量给药,和使用方法
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
CA2871386A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
EP2867253B1
(de)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl und herstellung massgeschneiderter, hochselektiver und multispezifischer targeting-einheiten mit mindestens zwei verschiedenen bindungseinheiten sowie verwendungen davon
|
KR20150023938A
(ko)
|
2012-07-04 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
항-테오필린 항체 및 이의 사용 방법
|
WO2014006123A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
CN104428006B
(zh)
|
2012-07-04 |
2017-09-08 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原‑抗体缀合物
|
CA2877009C
(en)
|
2012-07-05 |
2023-10-03 |
Devin TESAR |
Expression and secretion system
|
US20140030280A1
(en)
|
2012-07-09 |
2014-01-30 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates
|
TR201802376T4
(tr)
|
2012-07-09 |
2018-03-21 |
Genentech Inc |
Anti-CD79b antikorları içeren immünokonjugatlar.
|
WO2014011518A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
MX2015000315A
(es)
|
2012-07-09 |
2015-07-06 |
Genentech Inc |
Anticuerpos anti-cd22 e inmunoconjugados.
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
US9695233B2
(en)
|
2012-07-13 |
2017-07-04 |
Roche Glycart Ag |
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014023679A1
(en)
|
2012-08-07 |
2014-02-13 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
PE20150645A1
(es)
|
2012-08-08 |
2015-05-11 |
Roche Glycart Ag |
Proteinas de fusion de interleuquina 10 y usos de las mismas
|
WO2014023709A1
(en)
|
2012-08-09 |
2014-02-13 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JP6444874B2
(ja)
|
2012-10-08 |
2018-12-26 |
ロシュ グリクアート アーゲー |
2つのFabフラグメントを含むFc不含抗体および使用方法
|
SI2908912T1
(sl)
|
2012-10-18 |
2021-03-31 |
The Rockefeller University |
Široko nevtralizirajoča protitelesa proti HIV
|
WO2014063194A1
(en)
|
2012-10-23 |
2014-05-01 |
The University Of Sydney |
Elastic hydrogel
|
US9163093B2
(en)
|
2012-11-01 |
2015-10-20 |
Abbvie Inc. |
Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
MX2015005757A
(es)
|
2012-11-08 |
2015-11-18 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
|
PH12019501031A1
(en)
|
2012-11-13 |
2022-11-14 |
Genentech Inc |
Anti-hemagglutinin antibodies and methods of use
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
EP2928512B1
(de)
|
2012-12-10 |
2018-08-15 |
Elastagen Pty Ltd |
Herstellung von skalierbarem dreidimensionalem elastischem konstrukt
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
CN104903352A
(zh)
|
2012-12-28 |
2015-09-09 |
艾伯维公司 |
多价结合蛋白组合物
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
EP2948177A1
(de)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Verfahren zur optimierung der domänenstabilität von bindungsproteinen
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
EP2948475A2
(de)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Verfahren und zusammensetzungen zur modulierung einer immunantwort
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2948478B1
(de)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antikörper gegen cdh19 für melanome
|
US9840559B2
(en)
|
2013-02-01 |
2017-12-12 |
The Regents Of The University Of California |
Anti-CD83 antibodies and use thereof
|
AU2014214530B2
(en)
|
2013-02-07 |
2014-10-16 |
Csl Limited |
IL-11R binding proteins and uses thereof
|
US20140228875A1
(en)
|
2013-02-08 |
2014-08-14 |
Nidus Medical, Llc |
Surgical device with integrated visualization and cauterization
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US9701743B2
(en)
|
2014-02-20 |
2017-07-11 |
Allergan, Inc. |
Complement component C5 antibodies
|
EP2958592A1
(de)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung von krebs und zur verhinderung von arzneimittelresistenz
|
CN110845618A
(zh)
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
UA119320C2
(uk)
|
2013-02-26 |
2019-06-10 |
Рош Глікарт Аг |
Активуюча т-клітини біспецифічна антигензв'язувальна молекула
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
AU2014223824B2
(en)
|
2013-02-28 |
2020-02-27 |
Albert Einstein College Of Medicine, Inc. |
Tuberculosis biomarkers and uses thereof
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
AU2013381687A1
(en)
|
2013-03-12 |
2015-09-24 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
BR112015022210A8
(pt)
|
2013-03-13 |
2018-01-23 |
Genentech Inc |
formulações de anticorpo
|
HUE049707T2
(hu)
|
2013-03-13 |
2020-11-30 |
Hoffmann La Roche |
Csökkent oxidációjú kiszerelések
|
EP2968494B1
(de)
|
2013-03-13 |
2018-11-14 |
Seattle Genetics, Inc. |
Aktivkohlefiltrierung zur reinigung von benzodiazepin-adcs
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
SG11201507043SA
(en)
|
2013-03-13 |
2015-10-29 |
Genentech Inc |
Formulations with reduced oxidation
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
BR112015023355A8
(pt)
|
2013-03-14 |
2018-01-30 |
Abbott Lab |
antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP2971046A4
(de)
|
2013-03-14 |
2016-11-02 |
Abbott Lab |
Monoklonale antikörper gegen hcv-core lipid-bindender domäne
|
KR20150127203A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
EP2968526A4
(de)
|
2013-03-14 |
2016-11-09 |
Abbott Lab |
Hcv-antigen-antikörper-kombinationstest sowie verfahren und zusammensetzungen zur verwendung darin
|
US10150813B2
(en)
|
2013-03-14 |
2018-12-11 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
BR112015022529A2
(pt)
|
2013-03-15 |
2017-07-18 |
Genentech Inc |
meios de cultura de células e processos de produção de anticorpo
|
EP2968537A1
(de)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
|
TW202146054A
(zh)
|
2013-03-15 |
2021-12-16 |
德商艾伯維德國有限及兩合公司 |
抗-egfr抗體藥物結合物調配物
|
EP2970452A2
(de)
|
2013-03-15 |
2016-01-20 |
AC Immune S.A. |
Anti-tau-antikörper und verfahren zur verwendung
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
CN105143265A
(zh)
|
2013-03-15 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
抗CRTh2抗体及其用途
|
US11634502B2
(en)
|
2013-03-15 |
2023-04-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
SG10201912621TA
(en)
|
2013-03-15 |
2020-02-27 |
Genentech Inc |
Cell culture compositions with antioxidants and methods for polypeptide production
|
NZ751264A
(en)
|
2013-03-15 |
2021-07-30 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
KR20150132864A
(ko)
|
2013-03-15 |
2015-11-26 |
애브비 인코포레이티드 |
항체 약물 접합체(adc) 정제
|
GB201306589D0
(en)
|
2013-04-11 |
2013-05-29 |
Abeterno Ltd |
Live cell imaging
|
ES2774976T3
(es)
|
2013-04-29 |
2020-07-23 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
WO2016071438A2
(en)
|
2014-11-05 |
2016-05-12 |
Agrosavfe Nv |
Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
|
JP6388917B2
(ja)
|
2013-04-29 |
2018-09-12 |
アグロサーフエ・エン・フエー |
ポリペプチドからなる農薬組成物
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
MX380702B
(es)
|
2013-05-30 |
2025-03-12 |
Kiniksa Pharmaceuticals Ltd |
Proteinas de union al antigeno del receptor de oncostatina m.
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
BR112016001461A2
(pt)
|
2013-07-23 |
2017-08-29 |
Biocon Ltd |
Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína
|
MY190252A
(en)
|
2013-08-02 |
2022-04-08 |
Pfizer |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
KR102488446B1
(ko)
|
2013-08-13 |
2023-01-13 |
앨러간 파마슈티컬스 인터내셔널 리미티드 |
손상 조직의 재생
|
RU2016109247A
(ru)
|
2013-09-17 |
2017-10-19 |
Дженентек, Инк. |
Способы применения антител к lgr5
|
NZ719036A
(en)
|
2013-09-27 |
2022-02-25 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CA2924559A1
(en)
|
2013-10-02 |
2015-04-09 |
Humabs Biomed Sa |
Neutralizing anti-influenza a antibodies and uses thereof
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
TW201940514A
(zh)
|
2013-10-18 |
2019-10-16 |
美商建南德克公司 |
抗-rspo抗體及使用方法
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
AU2014340129A1
(en)
|
2013-10-23 |
2016-05-26 |
Genentech, Inc. |
Methods of diagnosing and treating eosinophilic disorders
|
EP3069137A1
(de)
|
2013-11-05 |
2016-09-21 |
Novartis Ag |
Organische verbindungen
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
KR102202925B1
(ko)
|
2013-11-21 |
2021-01-14 |
에프. 호프만-라 로슈 아게 |
항-알파-시누클레인 항체 및 사용 방법
|
US10947319B2
(en)
|
2013-11-27 |
2021-03-16 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting HER2
|
RU2718054C2
(ru)
|
2013-11-28 |
2020-03-30 |
СиЭсЭл ЛИМИТЕД |
Способ лечения нефропатии
|
AU2014360704A1
(en)
|
2013-12-02 |
2016-05-19 |
Abbvie, Inc. |
Compositions and methods for treating osteoarthritis
|
US9309314B2
(en)
|
2013-12-03 |
2016-04-12 |
Agency For Science, Technology And Research (A*Star) |
Polypeptides, nucleic acids and uses thereof
|
NZ720769A
(en)
|
2013-12-09 |
2022-10-28 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of use thereof
|
AR098743A1
(es)
|
2013-12-13 |
2016-06-08 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33
|
EP2883883A1
(de)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
|
EP3083687A2
(de)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
|
WO2015095392A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
EP3083692B1
(de)
|
2013-12-17 |
2020-02-19 |
F.Hoffmann-La Roche Ag |
Verfahren zur behandlung von krebs mit pd-1-achsenbindenden antagonisten und taxanen
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
CA2932465C
(en)
|
2013-12-18 |
2023-08-22 |
Csl Limited |
Methods of treating wounds in a diabetic subject
|
CA2932958A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
KR102278429B1
(ko)
|
2014-01-03 |
2021-07-16 |
에프. 호프만-라 로슈 아게 |
공유 연결된 폴리펩티드 독소-항체 콘쥬게이트
|
RU2694981C2
(ru)
|
2014-01-03 |
2019-07-18 |
Ф. Хоффманн-Ля Рош Аг |
Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
|
CN111228509A
(zh)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
CN114671954A
(zh)
|
2014-01-10 |
2022-06-28 |
博笛生物科技有限公司 |
靶向her2阳性肿瘤的化合物和组合物
|
US20170043034A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
SG11201606490YA
(en)
|
2014-02-08 |
2016-09-29 |
Genentech Inc |
Methods of treating alzheimer's disease
|
TR201810635T4
(tr)
|
2014-02-12 |
2018-08-27 |
Hoffmann La Roche |
Anti-jagged1 antikorları ve kullanım yöntemleri.
|
CN106029693A
(zh)
|
2014-02-21 |
2016-10-12 |
豪夫迈·罗氏有限公司 |
抗il-13/il-17双特异性抗体及其用途
|
RU2673036C2
(ru)
|
2014-02-27 |
2018-11-21 |
Аллерган, Инк. |
АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
|
WO2015131155A1
(en)
|
2014-02-28 |
2015-09-03 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
AR099812A1
(es)
|
2014-03-21 |
2016-08-17 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
MA51552A
(fr)
|
2014-03-31 |
2021-03-24 |
Hoffmann La Roche |
Anticorps anti-ox40 et procédés d'utilisation
|
US9975957B2
(en)
|
2014-03-31 |
2018-05-22 |
Genentech, Inc. |
Anti-OX40 antibodies and methods of use
|
MX388380B
(es)
|
2014-04-18 |
2025-03-19 |
Acceleron Pharma Inc |
Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
JP6875129B2
(ja)
|
2014-05-08 |
2021-05-19 |
ノボダイアックス, インコーポレイテッド |
直接的な免疫組織化学アッセイ
|
EP3888690A3
(de)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
US10758614B2
(en)
|
2014-06-09 |
2020-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health |
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
|
US10758613B2
(en)
|
2014-06-09 |
2020-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health |
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
|
WO2015191568A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
WO2015191615A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
|
US10434174B2
(en)
|
2014-06-09 |
2019-10-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
|
WO2015191590A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
|
WO2015191610A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
|
EP3155015A1
(de)
|
2014-06-11 |
2017-04-19 |
F. Hoffmann-La Roche AG |
Anti-lgr5-antikörper und verwendungen davon
|
MA40008A
(fr)
|
2014-06-13 |
2021-05-05 |
Acceleron Pharma Inc |
Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
WO2015197736A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
SI3164492T1
(sl)
|
2014-07-03 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Sistem polipeptidne ekspresije
|
TWI691335B
(zh)
|
2014-07-09 |
2020-04-21 |
英屬開曼群島商博笛生物科技有限公司 |
用於治療腫瘤的抗pd-l1組合
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
US9914774B2
(en)
|
2014-07-11 |
2018-03-13 |
Genentech, Inc. |
Notch pathway inhibition
|
MX384364B
(es)
|
2014-07-11 |
2025-03-14 |
Ventana Med Syst Inc |
Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
|
CN107001442B
(zh)
|
2014-07-15 |
2021-04-27 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
Cd44的分离的多肽及其应用
|
TWI589591B
(zh)
|
2014-08-04 |
2017-07-01 |
赫孚孟拉羅股份公司 |
雙特異性t細胞活化抗原結合分子
|
AU2015308818B2
(en)
|
2014-08-28 |
2021-02-25 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified T-cells
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
EP3191518B1
(de)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
US9518118B2
(en)
|
2014-09-12 |
2016-12-13 |
Genentech, Inc. |
Anti-HER2 antibodies and immunoconjugates
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
SG11201701821QA
(en)
|
2014-09-15 |
2017-04-27 |
Genentech Inc |
Antibody formulations
|
MX2017003472A
(es)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-her2.
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
CN107206069A
(zh)
|
2014-10-10 |
2017-09-26 |
埃博灵克斯股份有限公司 |
Rsv感染的治疗
|
SG11201702699TA
(en)
|
2014-10-10 |
2017-04-27 |
Ablynx Nv |
Inhalation device for use in aerosol therapy of respiratory diseases
|
WO2016061389A2
(en)
|
2014-10-16 |
2016-04-21 |
Genentech, Inc. |
Anti-alpha-synuclein antibodies and methods of use
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
AU2015336946A1
(en)
|
2014-10-23 |
2017-04-13 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
CA2965170A1
(en)
|
2014-10-23 |
2016-04-28 |
Dendrocyte Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
IL251822B2
(en)
|
2014-10-29 |
2023-03-01 |
Teva Pharmaceuticals Australia Pty Ltd |
Variants of interferon alpha-2-b
|
EA036498B1
(ru)
|
2014-10-29 |
2020-11-17 |
Сиэтл Дженетикс, Инк. |
Дозировка и введение нефукозилированных анти-cd40 антител
|
CN114381521A
(zh)
|
2014-11-03 |
2022-04-22 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
MX2017005750A
(es)
|
2014-11-03 |
2017-12-15 |
Genentech Inc |
Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso.
|
CN108064308B
(zh)
|
2014-11-05 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
细菌中产生双链蛋白的方法
|
EP3215525B1
(de)
|
2014-11-05 |
2020-07-29 |
Genentech, Inc. |
Verfahren zur herstellung von zweikettigen proteinen in bakterien
|
CA2963974A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
KR20170080604A
(ko)
|
2014-11-10 |
2017-07-10 |
제넨테크, 인크. |
항-인터류킨-33 항체 및 그것의 용도
|
KR20230146133A
(ko)
|
2014-11-14 |
2023-10-18 |
에프. 호프만-라 로슈 아게 |
Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
US10434177B2
(en)
|
2014-11-17 |
2019-10-08 |
Carnegie Mellon University |
Activatable two-component photosensitizers
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
WO2016079076A1
(en)
|
2014-11-20 |
2016-05-26 |
F. Hoffmann-La Roche Ag |
T cell activating bispecific antigen binding molecules agiant folr1 and cd3
|
KR20240024318A
(ko)
|
2014-11-20 |
2024-02-23 |
에프. 호프만-라 로슈 아게 |
T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법
|
CN107207609B
(zh)
|
2014-11-20 |
2022-07-19 |
豪夫迈·罗氏有限公司 |
共同轻链和使用方法
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
EP3227336B1
(de)
|
2014-12-05 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Anti-cd79b-antikörper und verfahren zur verwendung
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
JP6862343B2
(ja)
|
2014-12-19 |
2021-04-21 |
アブリンクス エン.ヴェー. |
システイン結合ナノボディダイマー
|
TWI617580B
(zh)
|
2014-12-19 |
2018-03-11 |
中外製藥股份有限公司 |
抗c5抗體及使用方法
|
AU2015365168B2
(en)
|
2014-12-19 |
2021-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
|
EP3233120A4
(de)
|
2014-12-19 |
2018-05-30 |
Monash University |
Il-21-antikörper
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
CN107427574B
(zh)
|
2015-01-09 |
2022-02-08 |
阿达尔塔有限公司 |
Cxcr4结合分子
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
EP3247281B1
(de)
|
2015-01-23 |
2020-12-02 |
The University of North Carolina at Chapel Hill |
Vorrichtungen, systeme und verfahren zur vorklinischen ultraschallabbildung von patienten
|
CN114133450B
(zh)
|
2015-02-03 |
2023-09-22 |
国家健康与医学研究院 |
抗-Rho GTPase的构象单域抗体及其用途
|
EP3253784B1
(de)
|
2015-02-04 |
2020-05-06 |
Genentech, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
CN112142844A
(zh)
|
2015-02-05 |
2020-12-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
CA2976236A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
KR20170127011A
(ko)
|
2015-03-16 |
2017-11-20 |
제넨테크, 인크. |
Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
JP7037363B2
(ja)
|
2015-04-06 |
2022-03-16 |
アクセルロン ファーマ インコーポレイテッド |
Tgfベータスーパーファミリーi型およびii型受容体ヘテロ多量体およびその使用
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
CN107708733B
(zh)
|
2015-04-07 |
2022-11-15 |
艾利妥 |
抗分拣蛋白抗体和其使用方法
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
JP6815331B2
(ja)
|
2015-04-21 |
2021-01-20 |
ジェネンテック, インコーポレイテッド |
前立腺がんの分析のための組成物及び方法
|
CN115932273A
(zh)
|
2015-04-24 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
MX2017013807A
(es)
|
2015-04-30 |
2018-03-15 |
Harvard College |
Anticuerpos anti-proteina de union al lipido de adipocito humana (ap2) y agente de union al antigeno para tratar trastornos metabolicos.
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
EP3294771A1
(de)
|
2015-05-11 |
2018-03-21 |
H. Hoffnabb-La Roche Ag |
Zusammensetzungen und verfahren zur behandlung von lupus nephritis
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3095465A1
(de)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック, インコーポレイテッド |
癌のための治療方法及び診断方法
|
KR102661078B1
(ko)
|
2015-05-29 |
2024-05-23 |
애브비 인코포레이티드 |
항-cd40 항체 및 그의 용도
|
WO2016196343A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
CA2985818A1
(en)
|
2015-05-31 |
2016-12-08 |
Curegenix Corporation |
Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy
|
EP3302552A1
(de)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Zusammensetzungen und verfahren zur verwendung von anti-il-34-antikörpern zur behandlung von neurologischen erkrankungen
|
MA44955A
(fr)
|
2015-06-05 |
2019-03-20 |
Ac Immune Sa |
Anticorps anti-tau et leurs méthodes d'utilisation
|
MX2017015937A
(es)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
WO2016201388A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
CA2986928A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
EP3916018A1
(de)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3-antikörper und verfahren zur verwendung
|
EP3310378B1
(de)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1-antikörper und verfahren zur verwendung
|
AU2016278239B9
(en)
|
2015-06-17 |
2022-08-11 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
CN107787331B
(zh)
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗her2抗体和使用方法
|
AU2016280070B2
(en)
|
2015-06-17 |
2022-09-15 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
US9861621B2
(en)
|
2015-06-29 |
2018-01-09 |
Biomed Valley Discoveries, Inc. |
LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
AU2016288461B2
(en)
|
2015-06-29 |
2021-10-07 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
EP4302784A3
(de)
|
2015-06-30 |
2024-03-13 |
Seagen Inc. |
Anti-ntb-a-antikörper sowie zugehörige zusammensetzungen und verfahren
|
WO2017023866A1
(en)
|
2015-07-31 |
2017-02-09 |
Boston Biomedical, Inc. |
Method of targeting stat3 and other non-druggable proteins
|
JP7320350B2
(ja)
|
2015-08-04 |
2023-08-03 |
アクセルロン ファーマ インコーポレイテッド |
骨髄増殖性障害を処置するための方法
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EP4137158A1
(de)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Gegen moleküle gerichtete antigenbindende konstrukte
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
JP6914919B2
(ja)
|
2015-08-28 |
2021-08-04 |
ジェネンテック, インコーポレイテッド |
抗ヒプシン抗体及びその使用
|
WO2017046335A1
(en)
|
2015-09-18 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
CA2993423C
(en)
|
2015-09-18 |
2024-03-12 |
Chugai Seiyaku Kabushiki Kaisha |
Il-8-binding antibodies and uses thereof
|
WO2017050729A1
(en)
|
2015-09-22 |
2017-03-30 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
PE20181363A1
(es)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
Variantes optimizadas de anticuerpos anti-vegf
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
US10017572B2
(en)
|
2015-09-25 |
2018-07-10 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
WO2017055484A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining the metabolic status of lymphomas
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
PE20181092A1
(es)
|
2015-10-02 |
2018-07-09 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
JP7034066B2
(ja)
|
2015-10-02 |
2022-03-11 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する二重特異性抗体
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
CA2990755A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffman-La Roche Ag |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
US20170096495A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する四価の二重特異性抗体発明の分野
|
WO2017064034A1
(en)
|
2015-10-12 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
WO2017072210A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
EP3368074A2
(de)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-faktor-d-antikörper und -konjugate
|
CN108290957B
(zh)
|
2015-10-30 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
抗-HtrA1抗体及其使用方法
|
US11123430B2
(en)
|
2015-11-04 |
2021-09-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
EP3371217A1
(de)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Screening-verfahren für multispezifische antikörper
|
EP3374389A1
(de)
|
2015-11-13 |
2018-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-nkg2d-einzeldomänenantikörper und verwendungen davon
|
WO2017083914A1
(en)
|
2015-11-20 |
2017-05-26 |
Australian Biomedical Co. Pty Ltd |
Compounds for medicinal applications
|
EP3380121B1
(de)
|
2015-11-23 |
2023-12-20 |
Acceleron Pharma Inc. |
Actrii-antagonist zur verwendung in der behandlung von augenerkrankungen
|
TN2018000180A1
(en)
|
2015-11-27 |
2019-10-04 |
Ablynx Nv |
Polypeptides inhibiting cd40l
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
PE20240365A1
(es)
|
2015-12-18 |
2024-03-04 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso
|
JP6970090B2
(ja)
|
2015-12-18 |
2021-11-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
C末端リジンで結合体化された免疫グロブリン
|
SG11201804951SA
(en)
|
2015-12-30 |
2018-07-30 |
Genentech Inc |
Use of tryptophan derivatives for protein formulations
|
EP3397287A1
(de)
|
2015-12-30 |
2018-11-07 |
Genentech, Inc. |
Formulierungen mit reduziertem abbau von polysorbat
|
EP3400443B1
(de)
|
2016-01-04 |
2020-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verwendung von pd-1 und tim-3 zur messung von cd8+ zellen zur vorhersage und behandlung von nierenzellkarzinom
|
WO2017118307A1
(zh)
|
2016-01-05 |
2017-07-13 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
WO2017127764A1
(en)
|
2016-01-20 |
2017-07-27 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
WO2017129769A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
ES2924775T3
(es)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos y composición farmacéutica para el tratamiento del cáncer
|
WO2017136558A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック, インコーポレイテッド |
がんのための治療方法及び診断方法
|
MA45280B1
(fr)
|
2016-03-02 |
2021-08-31 |
Eisai R&D Man Co Ltd |
Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
|
CN116196412A
(zh)
|
2016-03-15 |
2023-06-02 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
EP3442584B1
(de)
|
2016-03-15 |
2021-07-28 |
Seagen Inc. |
Kombinationen von pbd-basierten antikörper-arzneimittelkonjugaten mit bcl-2-inhibitoren
|
MA43724B1
(fr)
|
2016-03-22 |
2023-06-28 |
Hoffmann La Roche |
Molécules bispécifiques de cellules t activées par une protéase
|
SI3433280T1
(sl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
S proteazo aktivirane bispecifične molekule celic T
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
JP7468992B2
(ja)
|
2016-03-29 |
2024-04-16 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
|
EP3231813A1
(de)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
|
EP3439659A1
(de)
|
2016-04-06 |
2019-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von altersbedingten kardiometabolischen erkrankungen
|
EP3865511A1
(de)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3-antikörper und verfahren zur verwendung
|
CA3020718A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
EP3445779A1
(de)
|
2016-04-22 |
2019-02-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von entzündlichen hauterkrankungen im zusammenhang mit desmoglein-1-mangel
|
EA037960B1
(ru)
|
2016-04-27 |
2021-06-15 |
Эббви Инк. |
Способ лечения эозинофильного эзофагита с применением антитела против il-13
|
JP2019523213A
(ja)
|
2016-05-02 |
2019-08-22 |
アブリンクス エン.ヴェー. |
Rsv感染の処置
|
MA56474A
(fr)
|
2016-05-02 |
2022-05-11 |
Hoffmann La Roche |
Contorsbody - liant de cible à chaîne unique
|
EP3452109A1
(de)
|
2016-05-03 |
2019-03-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Cd31shed als molekulares target zur bildgebung von entzündungen
|
EP3452092B1
(de)
|
2016-05-06 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmazeutische zusammensetzungen zur behandlung von chemoresistenter akuter myeloischer leukämie (aml)
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
EP3243836A1
(de)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
|
JP7285076B2
(ja)
|
2016-05-11 |
2023-06-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Tnfファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
|
EP3243832A1
(de)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
|
EP4122958A1
(de)
|
2016-05-13 |
2023-01-25 |
BioAtla, Inc. |
Anti-ror2-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
|
JP6585860B2
(ja)
|
2016-05-18 |
2019-10-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの処置のための抗pd1抗体及び抗lag3抗体
|
EP3458101B1
(de)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac-antikörper-konjugate und verfahren zur verwendung
|
US20190292259A1
(en)
|
2016-05-24 |
2019-09-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
WO2017214024A1
(en)
|
2016-06-06 |
2017-12-14 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
AU2017277916A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
CN116059394A
(zh)
|
2016-06-08 |
2023-05-05 |
艾伯维公司 |
抗egfr抗体药物偶联物
|
MX2018015280A
(es)
|
2016-06-08 |
2019-08-12 |
Abbvie Inc |
Conjugados de anticuerpo y farmaco anti-egfr.
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
BR112018075649A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
|
CN109562169A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
US20190153107A1
(en)
|
2016-06-08 |
2019-05-23 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
WO2017214462A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CN116284404A
(zh)
|
2016-06-08 |
2023-06-23 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
MY202858A
(en)
|
2016-06-10 |
2024-05-25 |
Eisai R&D Man Co Ltd |
Lysine conjugated immunoglobulins
|
KR102376582B1
(ko)
|
2016-06-17 |
2022-03-18 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체 및 사용 방법
|
JP7133477B2
(ja)
|
2016-06-24 |
2022-09-08 |
ジェネンテック, インコーポレイテッド |
抗ポリユビキチン多重特異性抗体
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
CN115305229A
(zh)
|
2016-07-13 |
2022-11-08 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
CN116531490A
(zh)
|
2016-07-15 |
2023-08-04 |
阿塞勒隆制药公司 |
用于治疗肺高血压的组合物和方法
|
WO2018014067A1
(en)
|
2016-07-19 |
2018-01-25 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd47 combination therapy
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
BR112019001615A2
(pt)
|
2016-07-27 |
2019-04-30 |
Acceleron Pharma Inc. |
métodos e composições para tratar mielofibrose
|
KR102591955B1
(ko)
|
2016-07-29 |
2023-10-19 |
추가이 세이야쿠 가부시키가이샤 |
증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
|
BR112019001693A2
(pt)
|
2016-07-29 |
2019-07-02 |
Ct Hospitalier Universitaire Toulouse |
anticorpos direcionados a macrófagos associados a tumores e seus usos
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
KR102538749B1
(ko)
|
2016-08-05 |
2023-06-01 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
EP3510407A1
(de)
|
2016-09-08 |
2019-07-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur diagnose und behandlung des nephrotischen syndroms
|
EP3512880A1
(de)
|
2016-09-15 |
2019-07-24 |
Ablynx NV |
Gegen makrophagenmigrationshemmenden faktor gerichte variable immunglobulin-einzeldomänen
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
AU2017331739A1
(en)
|
2016-09-23 |
2019-03-07 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
RS64550B1
(sr)
|
2016-09-23 |
2023-09-29 |
Hoffmann La Roche |
Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
|
CA3037961A1
(en)
|
2016-09-30 |
2018-04-05 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il23 specific antibody
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
CN110198743B
(zh)
|
2016-10-05 |
2023-07-18 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
MA46472A
(fr)
|
2016-10-05 |
2019-08-14 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
EP3522933B1
(de)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von antikörperarzneimittelkonjugaten
|
JP7579056B2
(ja)
|
2016-10-06 |
2024-11-07 |
ジェネンテック, インコーポレイテッド |
がんのための治療方法及び診断方法
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018075564A1
(en)
|
2016-10-17 |
2018-04-26 |
University Of Maryland, College Park |
Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
|
CN110366558A
(zh)
|
2016-10-28 |
2019-10-22 |
班扬生物标记公司 |
针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
CN109923128A
(zh)
|
2016-11-15 |
2019-06-21 |
基因泰克公司 |
用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
|
KR20190078648A
(ko)
|
2016-11-16 |
2019-07-04 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 방법
|
IL317416A
(en)
|
2016-11-16 |
2025-02-01 |
Ablynx Nv |
T cell-recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
US20210277145A1
(en)
|
2016-11-17 |
2021-09-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
JP7274417B2
(ja)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1bb結合タンパク質及びその使用
|
TWI797097B
(zh)
|
2016-11-28 |
2023-04-01 |
日商中外製藥股份有限公司 |
包含抗原結合域與運送部分的多胜肽
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
EP3548894B1
(de)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur diagnose eines nierenzellkarzinoms
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
AU2017373889B2
(en)
|
2016-12-07 |
2025-01-02 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
WO2018108759A1
(en)
|
2016-12-13 |
2018-06-21 |
F. Hoffmann-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
MX2019006866A
(es)
|
2016-12-16 |
2019-08-22 |
Merck Patent Gmbh |
Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica.
|
CA3039430A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
WO2018114748A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
GB201621806D0
(en)
|
2016-12-21 |
2017-02-01 |
Philogen Spa |
Immunocytokines with progressive activation mechanism
|
EP3360898A1
(de)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
|
CN108261544B
(zh)
|
2016-12-30 |
2023-05-05 |
江苏太平洋美诺克生物药业股份有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
CN108261391B
(zh)
|
2016-12-30 |
2022-03-01 |
江苏太平洋美诺克生物药业有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
WO2018127473A1
(en)
|
2017-01-03 |
2018-07-12 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
WO2018134389A1
(en)
|
2017-01-23 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating infections
|
MA47362A
(fr)
|
2017-01-30 |
2019-12-04 |
Janssen Biotech Inc |
Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
|
EP3576789B1
(de)
|
2017-02-01 |
2024-12-11 |
Zhejiang Shimai Pharmaceutical Co., Ltd. |
Monomere humane igg1-fc- und bispezifische antikörper
|
MX2019009377A
(es)
|
2017-02-07 |
2019-12-11 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
AR110873A1
(es)
|
2017-02-10 |
2019-05-08 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
CA3054623A1
(en)
|
2017-02-28 |
2018-09-07 |
Vib Vzw |
Means and methods for oral protein delivery
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
SG11201908547VA
(en)
|
2017-03-22 |
2019-10-30 |
Genentech Inc |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
AU2018237359B2
(en)
|
2017-03-22 |
2024-06-27 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
MA49355A
(fr)
|
2017-03-27 |
2020-02-05 |
Hoffmann La Roche |
Formats de récepteurs de liaison d'antigène améliorés
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
ES3010117T3
(en)
|
2017-03-27 |
2025-04-01 |
Hoffmann La Roche |
Improved antigen binding receptors
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
EP3601325B1
(de)
|
2017-03-28 |
2023-07-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neue arten von tau
|
TWI848907B
(zh)
|
2017-03-28 |
2024-07-21 |
美商建南德克公司 |
治療神經退化性疾病之方法
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体のための二重特異性抗原結合分子
|
EP3601346A1
(de)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
WO2018178936A1
(en)
|
2017-03-30 |
2018-10-04 |
Duke University |
Radiolabeled biomolecules and their use
|
ES2955852T3
(es)
*
|
2017-04-03 |
2023-12-07 |
Hoffmann La Roche |
Anticuerpos de unión a STEAP-1
|
CA3053357A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
AU2018247796A1
(en)
|
2017-04-04 |
2019-08-29 |
F. Hoffmann-La Roche Ag |
Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
|
SG11201909344SA
(en)
|
2017-04-05 |
2019-11-28 |
Hoffmann La Roche |
Anti-lag3 antibodies
|
EP4516809A2
(de)
|
2017-04-05 |
2025-03-05 |
F. Hoffmann-La Roche AG |
Bispezifische antikörper mit spezifischer bindung an pd1 und lag3
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
EP3612648A1
(de)
|
2017-04-18 |
2020-02-26 |
Université Libre de Bruxelles |
Biomarker und targets für proliferative erkrankungen
|
CA3064697A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
MA49131A
(fr)
|
2017-04-21 |
2020-03-25 |
Hoffmann La Roche |
Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
|
JP2020517695A
(ja)
|
2017-04-27 |
2020-06-18 |
テサロ, インコーポレイテッド |
リンパ球活性化遺伝子−3(lag−3)に対する抗体薬およびそれらの使用
|
KR20200016232A
(ko)
|
2017-05-05 |
2020-02-14 |
알라코스 인크. |
알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
|
EP3621990A1
(de)
|
2017-05-11 |
2020-03-18 |
VIB vzw |
Glykosylierung von variablen immunoglobulindomänen
|
EP3625251A1
(de)
|
2017-05-15 |
2020-03-25 |
University Of Rochester |
Breit neutralisierende monoklonale anti-influenza-antikörper und verwendungen davon
|
EP3403649A1
(de)
|
2017-05-16 |
2018-11-21 |
Bayer Pharma Aktiengesellschaft |
Inhibitoren und antagonisten von gpr84 zur behandlung von endometriose
|
US20200171022A1
(en)
|
2017-05-17 |
2020-06-04 |
Inserm (Institut National De La Santé Et Da La Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
CA3064443A1
(en)
*
|
2017-05-24 |
2018-11-29 |
Development Center For Biotechnology |
Humanized antibodies against globo h and uses thereof in cancer treatments
|
EP3406253A1
(de)
|
2017-05-24 |
2018-11-28 |
Bayer Aktiengesellschaft |
Inhibitoren und antagonisten von humanem pycr1
|
EP3409322A1
(de)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Behandlungsverfahren
|
KR102740376B1
(ko)
|
2017-06-02 |
2024-12-09 |
메르크 파텐트 게엠베하 |
Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
|
CN110997716B
(zh)
|
2017-06-02 |
2024-03-15 |
埃博灵克斯股份有限公司 |
结合聚集蛋白聚糖的免疫球蛋白
|
HRP20241562T1
(hr)
|
2017-06-02 |
2025-01-31 |
Merck Patent Gmbh |
Adamts vezujući imunoglobulini
|
US12129308B2
(en)
|
2017-06-02 |
2024-10-29 |
Merck Patent Gmbh |
MMP13 binding immunoglobulins
|
US20200096507A1
(en)
|
2017-06-08 |
2020-03-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Chimeric receptor for use in whole-cell sensors for detecting analytes of interest
|
US20210079100A1
(en)
|
2017-06-08 |
2021-03-18 |
Inserm (Institute National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating hyperpigmentation disorders
|
TWI726217B
(zh)
*
|
2017-06-15 |
2021-05-01 |
財團法人生物技術開發中心 |
含有抗globo h抗體之抗體-藥物共軛物及其用途
|
EP3641802A1
(de)
|
2017-06-22 |
2020-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von fibrose mit mitteln zur hemmung der aktivierung von mukosa-assoziierten invarianten t-zellen (mait)
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
WO2019016237A1
(en)
|
2017-07-19 |
2019-01-24 |
Vib Vzw |
AGENTS FOR CONNECTING TO SERUM ALBUMIN
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
EP3658173A1
(de)
|
2017-07-25 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur modulation von monozytopoese
|
KR20200036889A
(ko)
|
2017-07-28 |
2020-04-07 |
에프. 호프만-라 로슈 아게 |
이중특이성 항체 제형
|
MA47691A
(fr)
|
2017-08-03 |
2020-01-08 |
Alector Llc |
Anticorps anti-cd33 et leurs procédés d'utilisation
|
EP3444275A1
(de)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoklonaler antikörper anti-fgfr4
|
CN111511762A
(zh)
|
2017-08-21 |
2020-08-07 |
天演药业公司 |
抗cd137分子及其用途
|
WO2019043026A1
(en)
|
2017-08-30 |
2019-03-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTI-MESOTHELIC RADIOMARQUATED SINGLE DOMAIN ANTIBODIES SUITABLE FOR IMAGING AND TREATING CANCERS
|
PT3681911T
(pt)
|
2017-09-11 |
2024-12-18 |
Univ Monash |
Proteínas de ligação ao recetor humano da trombina, par4
|
EP3457139A1
(de)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antikörperähnliche peptide zur quantifizierung therapeutischer antikörper
|
CN111655340A
(zh)
|
2017-09-20 |
2020-09-11 |
国家医疗保健研究所 |
用于调节自噬的方法和药物组合物
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
CN111246885B
(zh)
|
2017-10-20 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
WO2019081456A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
|
CN111372947A
(zh)
|
2017-10-30 |
2020-07-03 |
豪夫迈·罗氏有限公司 |
在体内从单特异性抗体产生多特异性抗体的方法
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
EP3704160A1
(de)
|
2017-10-31 |
2020-09-09 |
VIB vzw |
Neuartige antigenbindende chimäre proteine und verfahren und verwendungen davon
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
EP3703746A1
(de)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Neuartige antigenbindende moleküle mit ligandentrimer der tnf-familie
|
MX2020004571A
(es)
|
2017-11-01 |
2020-08-24 |
Hoffmann La Roche |
Contorsbodies 2+1 biespecificos.
|
TW201930353A
(zh)
|
2017-11-01 |
2019-08-01 |
瑞士商赫孚孟拉羅股份公司 |
使用經靶向之ox40促效劑的組合療法
|
PL3707510T3
(pl)
|
2017-11-06 |
2024-09-30 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
MA50893A
(fr)
|
2017-11-15 |
2020-09-23 |
Novo Nordisk As |
Liants de facteur x renforçant l'activation fx
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
KR20200089311A
(ko)
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
|
BR112020010514A2
(pt)
|
2017-11-29 |
2020-11-24 |
Csl Limited |
método para tratar ou prevenir lesão por isquemia-reperfusão
|
KR20200090838A
(ko)
|
2017-12-01 |
2020-07-29 |
시애틀 지네틱스, 인크. |
유방암 치료를 위한 인간화된 항-liv1 항체
|
JP7391845B2
(ja)
|
2017-12-01 |
2023-12-05 |
シージェン インコーポレイテッド |
Cd47抗体及びがんを治療するためのその使用
|
TW201934578A
(zh)
|
2017-12-14 |
2019-09-01 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
EP3541837A4
(de)
|
2017-12-19 |
2020-05-13 |
The Rockefeller University |
Humane igg-fc-domänen-varianten mit verbesserter effektorfunktion
|
WO2019122052A2
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/wt1
|
CN111247429B
(zh)
|
2017-12-21 |
2025-03-28 |
豪夫迈·罗氏有限公司 |
用于新颖抗原结合模块的特异性测试的通用报告细胞测定法
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
JP2021508246A
(ja)
|
2017-12-21 |
2021-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規抗原結合部分の特異性試験のためのcar−t細胞アッセイ
|
EP3728321A1
(de)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Verwendung von pilra-bindenden mitteln zur behandlung einer erkrankung
|
AU2018396970A1
(en)
|
2017-12-28 |
2020-08-13 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
WO2019133512A1
(en)
|
2017-12-29 |
2019-07-04 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
EP3735590A1
(de)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von resistentem melanom
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
AU2019207276A1
(en)
|
2018-01-15 |
2020-09-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
US12145984B2
(en)
|
2018-01-24 |
2024-11-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33
|
CN111655730A
(zh)
|
2018-01-31 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
包含与lag3结合的抗原结合位点的双特异性抗体
|
WO2019152715A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
EP3746470A1
(de)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Stabilisierte immunoglobulindomänen
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
IL276200B2
(en)
|
2018-02-06 |
2025-01-01 |
Ablynx Nv |
Polypeptide comprising two variable domains of anti-human (vWF) immunoglobulins VON- for use in the treatment of a first episode of von Willebrand Factor (vWF)-related disease
|
MA51793A
(fr)
|
2018-02-08 |
2020-12-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
KR102417088B1
(ko)
|
2018-02-09 |
2022-07-07 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
AU2019216761B2
(en)
|
2018-02-09 |
2025-04-10 |
Acceleron Pharma Inc. |
Methods for treating heterotopic ossification
|
WO2019158675A1
(en)
|
2018-02-16 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating vitiligo
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
CA3092421A1
(en)
|
2018-03-01 |
2019-09-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
JP2021514648A
(ja)
|
2018-03-01 |
2021-06-17 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規の標的抗原結合部分のための特異性アッセイ
|
JP7516250B2
(ja)
|
2018-03-05 |
2024-07-16 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il-23特異的抗体を用いたクローン病の治療方法
|
ES2998140T3
(en)
|
2018-03-13 |
2025-02-19 |
Hoffmann La Roche |
Therapeutic combination of 4-1bb agonists with anti-cd20 antibodies
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
EP3765517A1
(de)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
|
JP2021515583A
(ja)
|
2018-03-14 |
2021-06-24 |
ベイジン シュアンイー ファーマサイエンシーズ カンパニー, リミテッド |
抗クローディン18.2抗体
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
TW202413402A
(zh)
|
2018-03-15 |
2024-04-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途
|
US11661452B2
(en)
|
2018-03-20 |
2023-05-30 |
WuXi Biologics Ireland Limited |
Anti-lag-3 antibody polypeptide
|
US12202894B2
(en)
|
2018-03-20 |
2025-01-21 |
WuXi Biologics Ireland Limited |
Anti-TIM-3 antibodies
|
EP4144372A3
(de)
|
2018-03-21 |
2023-06-14 |
ALX Oncology Inc. |
Antikörper gegen signalregulatorisches protein alpha und verfahren zur verwendung
|
PL3768701T3
(pl)
|
2018-03-23 |
2024-02-19 |
Université Libre de Bruxelles |
Cząsteczki agonistów sygnalizacji WNT
|
MX2020010028A
(es)
|
2018-03-29 |
2020-10-14 |
Genentech Inc |
Actividad lactogenica modulada en celulas de mamifero.
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
EP3775902B1
(de)
|
2018-04-04 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Diagnostische assays zum nachweis von tumorantigenen bei krebspatienten
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
CN112424601A
(zh)
|
2018-04-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
检测癌症患者中肿瘤抗原的诊断性测定法
|
EP3552631A1
(de)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
WO2019213384A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
EP3794024B1
(de)
|
2018-05-14 |
2023-05-10 |
Werewolf Therapeutics, Inc. |
Aktivierbare interleukin-2-polypeptide und verfahren zu ihrer verwendung
|
EP3794023A1
(de)
|
2018-05-14 |
2021-03-24 |
Werewolf Therapeutics, Inc. |
Aktivierbare interleukin-12-polypeptide und verfahren zu ihrer verwendung
|
AU2019269066B2
(en)
|
2018-05-18 |
2022-10-06 |
F. Hoffmann-La Roche Ag |
Targeted intracellular delivery of large nucleic acids
|
EP3569618A1
(de)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisierender cd73-antikörper
|
AU2019272885A1
(en)
|
2018-05-25 |
2020-11-26 |
Alector Llc |
Anti-SIRPA antibodies and methods of use thereof
|
EP3816182A4
(de)
|
2018-05-30 |
2022-07-13 |
Chugai Seiyaku Kabushiki Kaisha |
Ligandbindungsmolekül mit einzeldomänen-antikörper
|
TW202015739A
(zh)
|
2018-06-01 |
2020-05-01 |
日商衛材R&D企管股份有限公司 |
剪接調節抗體-藥物結合物及其使用方法
|
IL305047A
(en)
|
2018-06-01 |
2023-10-01 |
Eisai R&D Man Co Ltd |
Methods for using splicing modulators
|
WO2019233810A1
(en)
|
2018-06-04 |
2019-12-12 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
WO2019241730A2
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
MY205645A
(en)
|
2018-06-23 |
2024-11-02 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
EP3814377A2
(de)
|
2018-06-29 |
2021-05-05 |
Alector LLC |
Anti-sirp-beta1-antikörper und verfahren zur verwendung davon
|
DE202019005887U1
(de)
|
2018-07-03 |
2023-06-14 |
Marengo Therapeutics, Inc. |
Anti-TCR-Antikörpermoleküle und Verwendungen davon
|
CN112424228B
(zh)
|
2018-07-04 |
2024-08-09 |
豪夫迈·罗氏有限公司 |
新型双特异性激动性4-1bb抗原结合分子
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
EP3618928B1
(de)
|
2018-07-13 |
2023-01-18 |
Alector LLC |
Anti-sortilin-antikörper und verfahren zur verwendung davon
|
EP3824295A4
(de)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
Prädiktoren mit verzögerter wirkung nach behandlung mit anti-il23-spezifischem antikörper
|
EP3823611A1
(de)
|
2018-07-18 |
2021-05-26 |
Genentech, Inc. |
Verfahren zur behandlung von lungenkrebs mit einem pd-1-achsen-bindenden antagonisten, einem antimetabolit und einem platinmittel
|
BR112021000727A2
(pt)
|
2018-07-20 |
2021-04-13 |
Surface Oncology, Inc. |
Composições anti-cd112r e métodos
|
AU2019312831A1
(en)
|
2018-08-01 |
2021-02-18 |
Centre National De La Recherche Scientifique - Cnrs - |
Anti-BTN3a antibodies and their use in treating cancer or infectious disorders
|
SG11202101152QA
(en)
|
2018-08-03 |
2021-03-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
SG11202100601TA
(en)
|
2018-08-08 |
2021-02-25 |
Genentech Inc |
Use of tryptophan derivatives and l-methionine for protein formulation
|
PE20210343A1
(es)
|
2018-08-10 |
2021-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
AU2019331018A1
(en)
|
2018-08-31 |
2021-03-11 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
JP7444858B2
(ja)
|
2018-09-05 |
2024-03-06 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
喘息及びアレルギー性疾患を処置するための方法及び組成物
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
WO2020053147A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
|
US20220047701A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
EP3849545A1
(de)
|
2018-09-10 |
2021-07-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur behandlung von neurofibromatose
|
WO2020058201A1
(en)
|
2018-09-17 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases
|
AR114732A1
(es)
|
2018-09-18 |
2020-10-07 |
Hoffmann La Roche |
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
|
JP2022501332A
(ja)
|
2018-09-19 |
2022-01-06 |
ジェネンテック, インコーポレイテッド |
膀胱がんの治療方法および診断方法
|
CN113396160A
(zh)
|
2018-09-19 |
2021-09-14 |
国家医疗保健研究所 |
治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
|
JP7475336B2
(ja)
|
2018-09-21 |
2024-04-26 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳癌のための診断方法
|
AU2019346134C1
(en)
|
2018-09-24 |
2024-06-20 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
EP3856772A1
(de)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verwendung von antagonisten von th17-zytokinen zur behandlung von bronchialer remodellierung bei patienten mit allergischem asthma
|
CN113286812A
(zh)
|
2018-09-27 |
2021-08-20 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
EP3861025A1
(de)
|
2018-10-01 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Bispezifische antigenbindende moleküle mit dreiwertiger bindung an cd40
|
MX2021003548A
(es)
|
2018-10-01 |
2021-05-27 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
|
WO2020070240A1
(en)
|
2018-10-04 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
|
US20210355216A1
(en)
|
2018-10-05 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
EP3636657A1
(de)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatographiefreies antikörperreinigungsverfahren
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
JP2022512648A
(ja)
|
2018-10-09 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
心筋線維化の処置のためのαV-インテグリン(CD51)阻害剤の使用
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
WO2020079162A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for inducing full ablation of hematopoiesis
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
CN113056287A
(zh)
|
2018-10-24 |
2021-06-29 |
豪夫迈·罗氏有限公司 |
缀合的化学降解诱导剂及使用方法
|
CN113260626B
(zh)
|
2018-11-05 |
2024-09-13 |
豪夫迈·罗氏有限公司 |
在原核宿主细胞中产生双链蛋白质的方法
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
TW202430572A
(zh)
|
2018-11-13 |
2024-08-01 |
美商坎伯斯治療有限責任公司 |
對抗檢查點分子之多特異性結合構築體及其用途
|
AU2019383017A1
(en)
|
2018-11-20 |
2021-06-03 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
|
EP3883961A1
(de)
|
2018-11-20 |
2021-09-29 |
Takeda Vaccines, Inc. |
Neuartige zika-virus-antikörper und ihre verwendungen
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
MX2021005878A
(es)
|
2018-12-13 |
2021-07-16 |
Eisai R&D Man Co Ltd |
Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso.
|
WO2020120644A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New anti tau svqivykpv epitope single domain antibody
|
EP3897722A4
(de)
|
2018-12-18 |
2022-09-14 |
Janssen Biotech, Inc. |
Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
TWI829831B
(zh)
|
2018-12-21 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合cd3之抗體
|
AU2019405782A1
(en)
|
2018-12-21 |
2021-06-17 |
23Andme, Inc. |
Anti-IL-36 antibodies and methods of use thereof
|
SG11202106116QA
(en)
|
2018-12-21 |
2021-07-29 |
Genentech Inc |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
AR117728A1
(es)
|
2018-12-21 |
2021-08-25 |
Hoffmann La Roche |
Moléculas superagonistas de unión al antígeno cd28 con diana tumoral
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
MA54513A
(fr)
|
2018-12-21 |
2022-03-30 |
Hoffmann La Roche |
Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
|
SG11202106498XA
(en)
|
2018-12-26 |
2021-07-29 |
Xilio Development Inc |
Anti-ctla4 antibodies and methods of use thereof
|
EP3902830A1
(de)
|
2018-12-30 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Antikörper gegen karnickel-cd19 und verfahren zur verwendung
|
MX2021008121A
(es)
|
2019-01-03 |
2021-12-10 |
Inst Nat Sante Rech Med |
Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
|
MX2021008434A
(es)
|
2019-01-14 |
2021-09-23 |
Genentech Inc |
Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
MA54750A
(fr)
|
2019-01-15 |
2021-11-24 |
Janssen Biotech Inc |
Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile
|
JP2022518250A
(ja)
|
2019-01-23 |
2022-03-14 |
ヤンセン バイオテツク,インコーポレーテツド |
乾癬性関節炎の治療方法で使用するための抗tnf抗体組成物
|
MX2021008561A
(es)
|
2019-01-23 |
2021-08-19 |
Genentech Inc |
Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
CN113348178A
(zh)
|
2019-01-28 |
2021-09-03 |
枫叶生物技术有限公司 |
用于治疗肺、肾或肝的纤维化疾病的psmp拮抗剂
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
EP3921031A1
(de)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und zusammensetzungen zur modulation der blut-gehirn-schranke
|
EP3921443A1
(de)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnose- und therapieverfahren für krebs
|
BR112021016348A2
(pt)
|
2019-02-18 |
2021-11-23 |
Atb Therapeutics |
Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira
|
WO2020169698A1
(en)
|
2019-02-21 |
2020-08-27 |
F. Hoffmann-La Roche Ag |
Sensitization of cancer cells to tnf by bet inhibition
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
AU2020228383A1
(en)
|
2019-02-27 |
2021-09-23 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
|
PH12021551720A1
(en)
|
2019-03-01 |
2022-03-28 |
Allogene Therapeutics Inc |
Dll3 targeting chimeric antigen receptors and binding agents
|
WO2020178313A1
(en)
|
2019-03-05 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New biomarkers and biotargets in renal cell carcinoma
|
MX2021010565A
(es)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
|
WO2020185763A1
(en)
|
2019-03-11 |
2020-09-17 |
Memorial Sloan Kettering Cancer Center |
Cd22 antibodies and methods of using the same
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
WO2020186176A1
(en)
|
2019-03-14 |
2020-09-17 |
Genentech, Inc. |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
US12122825B2
(en)
|
2019-03-14 |
2024-10-22 |
Janssen Biotech, Inc. |
Nucleic acid molecule encoding, and method of producing, a recombinant anti-tumor necrosis factor (TNF) antibody
|
MA55284A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de production de compositions d'anticorps anti-tnf
|
JP7660067B2
(ja)
|
2019-03-14 |
2025-04-10 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
JP7379654B2
(ja)
|
2019-03-15 |
2023-11-14 |
カーティザン セラピューティクス,インコーポレーテッド |
抗bcmaキメラ抗原受容体
|
MX2021011328A
(es)
|
2019-03-18 |
2021-12-10 |
Janssen Biotech Inc |
Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
CN113631573B
(zh)
|
2019-03-25 |
2024-06-04 |
国家医疗保健研究所 |
抗Tau抗体及其在制备用于治疗疾病的药物中的用途
|
US20220249511A1
(en)
|
2019-03-29 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
MX2021011609A
(es)
|
2019-03-29 |
2022-01-24 |
Genentech Inc |
Moduladores de interacciones de proteinas de superficie celular y metodos y composiciones relacionados con estos.
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
WO2020201442A1
(en)
|
2019-04-03 |
2020-10-08 |
Orega Biotech |
Combination therapies based on pd1 and il-17b inhibitors
|
US20220249458A1
(en)
|
2019-04-04 |
2022-08-11 |
Bayer Aktiengesellschaft |
Agonists Of Adiponectin
|
CA3133163A1
(en)
|
2019-04-09 |
2020-10-15 |
Matthias Schneider |
Protein binders for irhom2
|
CN113692414A
(zh)
|
2019-04-12 |
2021-11-23 |
豪夫迈·罗氏有限公司 |
使用CEA CD3双特异性抗体和Wnt信号传导抑制剂的癌症治疗
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
TW202043291A
(zh)
|
2019-04-19 |
2020-12-01 |
美商建南德克公司 |
抗mertk抗體及使用方法
|
EP3959305A1
(de)
|
2019-04-26 |
2022-03-02 |
Allogene Therapeutics, Inc. |
Verfahren zur herstellung allogener car-t-zellen
|
EP3963109A1
(de)
|
2019-04-30 |
2022-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von melanom
|
KR20220004744A
(ko)
|
2019-05-03 |
2022-01-11 |
제넨테크, 인크. |
항-pd-l1 항체를 이용하여 암을 치료하는 방법
|
EP3962493A2
(de)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Verfahren zur modulation der immunreaktivität/konzentration von irf oder sting oder zur behandlung von krebs mit der verabreichung eines sting-modulators und/oder eines purinergischen rezeptormodulators oder eines postzellularen signalisierungsfaktors
|
US12150813B2
(en)
|
2019-05-10 |
2024-11-26 |
The University Of North Carolina At Chapel Hill |
Methods, systems, and computer readable media for generating super-resolution images of microvasculature using ultrasound
|
AU2020275415A1
(en)
|
2019-05-14 |
2021-11-25 |
Genentech, Inc. |
Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
AU2020279987A1
(en)
|
2019-05-23 |
2021-11-18 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
EP3976650A1
(de)
|
2019-05-28 |
2022-04-06 |
Vib Vzw |
Krebsbehandlung durch abzielen auf plexine im immunbereich
|
US20220228116A1
(en)
|
2019-05-28 |
2022-07-21 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
CN114173873A
(zh)
|
2019-06-03 |
2022-03-11 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
EP3976648A1
(de)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
|
AU2020288499A1
(en)
|
2019-06-05 |
2022-01-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site-binding molecule
|
CN114127277A
(zh)
|
2019-06-05 |
2022-03-01 |
中外制药株式会社 |
蛋白酶底物和包含蛋白酶切割序列的多肽
|
US20220253669A1
(en)
|
2019-06-07 |
2022-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Information processing system, information processing method, program, and method for producing antigen-binding molecule or protein
|
KR20220031616A
(ko)
|
2019-06-11 |
2022-03-11 |
알렉터 엘엘씨 |
치료요법에 사용하기 위한 항-소르틸린 항체
|
EP3986453A1
(de)
|
2019-06-20 |
2022-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Konformationale anti-protease-nexin-1-einzeldomänenantikörper und verwendungen davon
|
MX2021015888A
(es)
|
2019-06-26 |
2022-03-22 |
Hoffmann La Roche |
Fusión de un anticuerpo que se une a cea y 4-1bbl.
|
JP7354306B2
(ja)
|
2019-06-27 |
2023-10-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
新規icos抗体及びそれらを含む腫瘍標的化抗原結合分子
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
BR112022001045A2
(pt)
|
2019-07-22 |
2022-07-19 |
Seagen Inc |
Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
|
BR112022001733A2
(pt)
|
2019-07-31 |
2022-06-28 |
Alector Llc |
Anticorpos anti-ms4a4a e métodos de uso dos mesmos
|
EP4004045A1
(de)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
An gprc5d bindende antikörper
|
WO2021018859A2
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
CN114401743A
(zh)
|
2019-08-02 |
2022-04-26 |
法国国家健康和医学研究院 |
中和颗粒酶b用于向经历过心肌梗塞的受试者提供心脏保护
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
CN114340675A
(zh)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
PH12022550646A1
(en)
|
2019-09-18 |
2023-04-03 |
Genentech Inc |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
US11918649B2
(en)
|
2019-09-18 |
2024-03-05 |
Molecular Templates, Inc. |
PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
|
JP2022549218A
(ja)
|
2019-09-20 |
2022-11-24 |
ジェネンテック, インコーポレイテッド |
抗トリプターゼ抗体の投薬
|
TWI764291B
(zh)
|
2019-09-24 |
2022-05-11 |
財團法人工業技術研究院 |
抗tigit抗體及使用方法
|
US20220324962A1
(en)
|
2019-09-27 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
EP4036116A4
(de)
|
2019-09-27 |
2024-01-24 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-vhh-domänen-antikörper und verwendung davon
|
CA3151406A1
(en)
|
2019-09-27 |
2021-04-01 |
Raymond D. Meng |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
WO2021064009A1
(en)
|
2019-09-30 |
2021-04-08 |
Scirhom Gmbh |
Protein binders to irhom2 epitopes
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
PE20221412A1
(es)
|
2019-10-02 |
2022-09-20 |
Boehringer Ingelheim Int |
Proteinas de fijacion multiespecificas para tratamiento contra el cancer
|
US20220354811A1
(en)
|
2019-10-03 |
2022-11-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
EP4037710A1
(de)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von eierstockkrebs, brustkrebs oder bauchspeicheldrüsenkrebs
|
CN118557751A
(zh)
|
2019-10-18 |
2024-08-30 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
WO2021078359A1
(en)
|
2019-10-21 |
2021-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of cubilin for the treatment of chronic kidney diseases
|
BR112022008652A2
(pt)
|
2019-11-05 |
2022-07-19 |
Hoffmann La Roche |
Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
BR112022008756A2
(pt)
|
2019-11-07 |
2022-07-26 |
Eisai R&D Man Co Ltd |
Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
|
US20220390449A1
(en)
|
2019-11-12 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New serological marker for the latent form of toxoplasmosis
|
JP2023503258A
(ja)
|
2019-11-14 |
2023-01-27 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能サイトカインポリペプチド及びその使用方法
|
PE20221462A1
(es)
|
2019-11-15 |
2022-09-21 |
Pliant Therapeutics Inc |
Composiciones y metodos para la activacion de integrinas
|
CN114728065A
(zh)
|
2019-11-26 |
2022-07-08 |
上海岸迈生物科技有限公司 |
针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
|
WO2021110796A1
(en)
|
2019-12-04 |
2021-06-10 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
US11897968B2
(en)
|
2019-12-13 |
2024-02-13 |
Alector Llc |
Anti-MerTK antibodies and methods of use thereof
|
US11845799B2
(en)
|
2019-12-13 |
2023-12-19 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
WO2021127217A1
(en)
|
2019-12-17 |
2021-06-24 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
MX2022007635A
(es)
|
2019-12-18 |
2022-07-19 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4.
|
CN115298213A
(zh)
|
2019-12-19 |
2022-11-04 |
奎多公司 |
单克隆抗体融合
|
CN114829408B
(zh)
|
2019-12-20 |
2024-01-26 |
山东博安生物技术股份有限公司 |
用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
|
BR112022012546A2
(pt)
|
2019-12-23 |
2022-09-06 |
Eisai R&D Man Co Ltd |
Método para produzir conjugado anticorpo-fármaco à base de eribulina
|
WO2021133723A2
(en)
|
2019-12-23 |
2021-07-01 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
WO2021131021A1
(ja)
|
2019-12-27 |
2021-07-01 |
中外製薬株式会社 |
抗ctla-4抗体およびその使用
|
EP4087866A1
(de)
|
2020-01-09 |
2022-11-16 |
F. Hoffmann-La Roche AG |
Neue 4-1bbl-trimer-haltige antigenbindende moleküle
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
WO2021144426A1
(en)
|
2020-01-17 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CA3164559A1
(en)
|
2020-01-31 |
2021-08-05 |
Lars Mueller |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
IL295387A
(en)
|
2020-02-05 |
2022-10-01 |
Larimar Therapeutics Inc |
Tat peptide binding proteins and uses thereof
|
EP4105237A4
(de)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co., Ltd. |
Cldn18.2-antikörper und verwendung davon
|
CN115461373B
(zh)
|
2020-02-10 |
2024-03-29 |
上海诗健生物科技有限公司 |
密蛋白18.2的抗体及其用途
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
JP2023514957A
(ja)
|
2020-02-28 |
2023-04-12 |
オレガ・バイオテック |
Ctla4阻害剤及びil-17b阻害剤に基づく複合療法
|
WO2021183849A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
EP4121163A1
(de)
|
2020-03-19 |
2023-01-25 |
Genentech, Inc. |
Isoformselektive anti-tgf-beta-antikörper und verwendungsverfahren
|
JP2023519213A
(ja)
|
2020-03-24 |
2023-05-10 |
ジェネンテック, インコーポレイテッド |
Tie2結合剤および使用方法
|
KR20220159426A
(ko)
|
2020-03-26 |
2022-12-02 |
제넨테크, 인크. |
감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
|
EP4126970A4
(de)
|
2020-03-31 |
2024-05-01 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur herstellung multispezifischer antigenbindender moleküle
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
US20230110053A1
(en)
|
2020-03-31 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
EP4126934A1
(de)
|
2020-04-01 |
2023-02-08 |
University of Rochester |
Monoklonale antikörper gegen das hämagglutinin (ha) und die neuraminidase (na) von influenza-h3n2-viren
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP4135848A2
(de)
|
2020-04-15 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Immunokonjugate
|
US20230279115A1
(en)
|
2020-04-22 |
2023-09-07 |
Mabwell (shanghai) Bioscience Co., Ltd. |
Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
|
WO2021217051A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
CA3178472A1
(en)
|
2020-04-24 |
2021-10-28 |
F. Hoffmann-La Roche Ag |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
SG11202112792WA
(en)
|
2020-04-28 |
2021-12-30 |
Univ Rockefeller |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
EP4143345A1
(de)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
|
TW202200212A
(zh)
|
2020-05-03 |
2022-01-01 |
中國大陸商聯寧(蘇州)生物製藥有限公司 |
包含抗-trop-2抗體之抗體藥物結合物
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
CN115836084A
(zh)
|
2020-05-15 |
2023-03-21 |
阿珀吉尼科斯股份公司 |
多特异性免疫调节剂
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
WO2021236225A1
(en)
|
2020-05-20 |
2021-11-25 |
Takeda Vaccines, Inc. |
Method for detection of zika virus specific antibodies
|
US20230324404A1
(en)
|
2020-05-20 |
2023-10-12 |
Takeda Vaccines, Inc. |
Method for detection of zika virus specific antibodies
|
WO2021236223A1
(en)
|
2020-05-20 |
2021-11-25 |
Takeda Vaccines, Inc. |
Method for determining the potency of antigens
|
CN115667307A
(zh)
|
2020-05-20 |
2023-01-31 |
居里研究所 |
合成的单域文库
|
JP2023528293A
(ja)
|
2020-05-20 |
2023-07-04 |
アンスティテュ・クリー |
単一ドメイン抗体及びがん治療におけるその使用
|
AU2021276930A1
(en)
|
2020-05-21 |
2023-02-02 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
IL298668A
(en)
|
2020-05-29 |
2023-01-01 |
23Andme Inc |
Anti-cd200r1 antibodies and methods of use thereof
|
WO2021245224A1
(en)
|
2020-06-05 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
WO2021248005A1
(en)
|
2020-06-05 |
2021-12-09 |
Eisai R&D Management Co., Ltd. |
Anti-bcma antibody-drug conjugates and methods of use
|
AU2021288916A1
(en)
|
2020-06-08 |
2022-11-24 |
F.Hoffmann-La Roche Ag |
Anti-HBV antibodies and methods of use
|
BR112022025227A2
(pt)
|
2020-06-11 |
2023-01-03 |
Genentech Inc |
Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
JP2023531406A
(ja)
|
2020-06-16 |
2023-07-24 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳がんを処置するための方法および組成物
|
WO2021257679A1
(en)
|
2020-06-17 |
2021-12-23 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
AU2021293507A1
(en)
|
2020-06-18 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
|
IL296089A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Antibodies binding to cd3
|
EP4168446A1
(de)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antikörper mit bindung an cd3 und folr1
|
AU2021291011A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and CD19
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
EP4168444A1
(de)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Proteaseaktivierte t-zell-bispezifische antikörper
|
WO2021259880A1
(en)
|
2020-06-22 |
2021-12-30 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
JP2023530760A
(ja)
|
2020-06-23 |
2023-07-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を標的とするアゴニストCD28抗原結合分子
|
CN115943158A
(zh)
|
2020-06-24 |
2023-04-07 |
基因泰克公司 |
抗细胞凋亡的细胞系
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd3/抗cd28二重特異性抗原結合分子
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
EP4153636A1
(de)
|
2020-06-29 |
2023-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Einzeldomänenantikörper gegen protein s und polypeptide damit
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
CN115812149A
(zh)
|
2020-07-13 |
2023-03-17 |
基因泰克公司 |
用于预测多肽免疫原性的基于细胞的方法
|
AU2021308653A1
(en)
|
2020-07-17 |
2023-02-16 |
Genentech, Inc. |
Anti-Notch2 antibodies and methods of use
|
EP4185328A1
(de)
|
2020-07-21 |
2023-05-31 |
Genentech, Inc. |
Antikörperkonjugierte chemische induktoren des abbaus von brm und verfahren dafür
|
WO2022023379A1
(en)
|
2020-07-28 |
2022-02-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for preventing and treating a cancer
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
EP4188443A4
(de)
|
2020-07-30 |
2024-09-18 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von psoriasis bei pädiatrischen patienten mit anti-il12/il23-antikörper
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
CN115836122A
(zh)
|
2020-08-07 |
2023-03-21 |
基因泰克公司 |
用于预测多肽免疫原性的基于t细胞的方法
|
KR20230048435A
(ko)
|
2020-08-17 |
2023-04-11 |
에이티비 테라퓨틱스 |
리보톡신 또는 RNAse를 포함하는 재조합 면역독소
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
TW202227625A
(zh)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
宿主細胞蛋白質之CRISPR/Cas9多重剔除
|
WO2022047381A1
(en)
|
2020-08-31 |
2022-03-03 |
Genentech, Inc. |
Methods for producing antibodies
|
KR20230086690A
(ko)
|
2020-09-14 |
2023-06-15 |
아이크노스 사이언스 에스. 아. |
Il1rap에 결합하는 항체 및 이의 용도
|
CA3196737A1
(en)
|
2020-09-24 |
2022-03-31 |
Massimiliano Mazzone |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
AU2021350075A1
(en)
|
2020-09-24 |
2023-03-09 |
F. Hoffmann-La Roche Ag |
Prevention or mitigation of T-cell bispecific antibody-related adverse effects
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
US20220112274A1
(en)
|
2020-09-28 |
2022-04-14 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
WO2022072523A1
(en)
|
2020-09-30 |
2022-04-07 |
Seagen Inc. |
Uveal melanoma treatment using sea-cd40
|
AU2021358031A1
(en)
|
2020-10-05 |
2023-05-04 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
EP4226155A1
(de)
|
2020-10-09 |
2023-08-16 |
Takeda Vaccines, Inc. |
Verfahren zur bestimmung komplementfixierender antikörper
|
EP4229090A1
(de)
|
2020-10-16 |
2023-08-23 |
Université d'Aix-Marseille |
Anti-gpc4-einzeldomänenantikörper
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
JP2023545566A
(ja)
|
2020-10-20 |
2023-10-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法
|
EP4232474A1
(de)
|
2020-10-21 |
2023-08-30 |
Boehringer Ingelheim International GmbH |
Bispezifische anti-vegf- und anti-trkb-bindende moleküle zur behandlung von augenerkrankungen
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
CN116635419A
(zh)
|
2020-10-30 |
2023-08-22 |
豪夫迈·罗氏有限公司 |
使用CEA CD3双特异性抗体和TGFβ信号传导抑制剂的癌症治疗
|
TW202227481A
(zh)
|
2020-11-04 |
2022-07-16 |
美國洛克菲勒大學 |
中和抗sars-cov-2抗體
|
EP4240492A2
(de)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-cd20/anti-cd3-antikörpern
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
TW202225191A
(zh)
|
2020-11-04 |
2022-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス,インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|
EP4240761A1
(de)
|
2020-11-05 |
2023-09-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verwendung von il-6-inhibitoren zur behandlung des akuten brustsyndroms bei patienten mit sichelzellanämie
|
IL302570A
(en)
|
2020-11-10 |
2023-07-01 |
Hoffmann La Roche |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
AU2021376837A1
(en)
|
2020-11-16 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
WO2022101458A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted cd40 agonists
|
US20230416830A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
AU2021381455A1
(en)
|
2020-11-23 |
2023-06-29 |
Genentech, Inc. |
Methods for modulating host cell surface interactions with sars-cov-2
|
TWI838663B
(zh)
|
2020-11-27 |
2024-04-11 |
美商建南德克公司 |
調節人類巨細胞病毒與宿主細胞表面交互作用之方法
|
AU2021392625A1
(en)
|
2020-12-01 |
2023-07-06 |
Genentech, Inc. |
Biological vesicles displaying cell surface proteins and methods related to same
|
EP4255930A1
(de)
|
2020-12-02 |
2023-10-11 |
Alector LLC |
Verfahren zur verwendung von anti-sortilin-antikörpern
|
PE20240819A1
(es)
|
2020-12-17 |
2024-04-18 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
EP4262976A1
(de)
|
2020-12-21 |
2023-10-25 |
Flagship Pioneering Innovations V, Inc. |
Verwendung von zellturn-faktoren zur erhöhung der geweberegeneration
|
WO2022148732A1
(en)
|
2021-01-06 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
KR20230146521A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항체-피롤로벤조디아제핀 유도체 접합체
|
AU2022208361A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Anti-dll3 antibody-drug conjugate
|
JP2024505428A
(ja)
|
2021-01-14 |
2024-02-06 |
アンスティテュ キュリー |
Her2単一ドメイン抗体バリアントおよびそのcar
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CN116917326A
(zh)
|
2021-01-22 |
2023-10-20 |
博泰康医药公司 |
抗her-2/trop-2构建体及其用途
|
US20230390411A1
(en)
|
2021-01-28 |
2023-12-07 |
Nanjing Chempion Biotechnology Co., Ltd. |
Conjugate and use thereof
|
CN117241804A
(zh)
|
2021-02-17 |
2023-12-15 |
非营利性组织佛兰芒综合大学生物技术研究所 |
在癌症治疗中slc4a4的抑制
|
IL305301A
(en)
|
2021-02-19 |
2023-10-01 |
Us Health |
SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
|
US12180521B2
(en)
|
2021-02-19 |
2024-12-31 |
Theripion, Inc. |
Paraoxonase fusion polypeptides and related compositions and methods
|
JP2024512253A
(ja)
|
2021-02-22 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
宿主細胞の表面とヘルペスウイルスとの相互作用を調節するための方法
|
WO2022180172A1
(en)
|
2021-02-26 |
2022-09-01 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
JP2024508488A
(ja)
|
2021-03-01 |
2024-02-27 |
エクシリオ デベロップメント, インコーポレイテッド |
がんを治療するためのマスクされたctla4及びpd1/pd-l1抗体の組み合わせ
|
EP4301467A1
(de)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Kombination von ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
|
BR112023017035A2
(pt)
|
2021-03-01 |
2024-02-06 |
New York Soc For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surger |
Anticorpos humanizados contra irhom2, ácido nucleico, uso do anticorpo, composição farmacêutica, composição, método de tratamento e kit terapêutico
|
US20240181073A1
(en)
|
2021-03-03 |
2024-06-06 |
Sorrento Therapeutics, Inc. |
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
|
BR112023018400A2
(pt)
|
2021-03-12 |
2023-12-12 |
Janssen Biotech Inc |
Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
|
EP4304732A1
(de)
|
2021-03-12 |
2024-01-17 |
Genentech, Inc. |
Anti-klk7-antikörper, anti-klk5-antikörper, multispezifische anti-klk5/klk7-antikörper und verfahren zur verwendung
|
IL305802A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
|
MX2023010812A
(es)
|
2021-03-15 |
2023-09-27 |
Genentech Inc |
Composiciones y metodos para tratar la nefritis lupica.
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
BR112023017490A2
(pt)
|
2021-03-17 |
2023-11-07 |
Receptos Llc |
Métodos de tratamento de dermatite atópica com anticorpos anti il-13
|
US20220306700A1
(en)
|
2021-03-17 |
2022-09-29 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
CA3212398A1
(en)
|
2021-03-17 |
2022-09-22 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗tmem106b抗体、及び、その使用方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
EP4313317A1
(de)
|
2021-03-23 |
2024-02-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur diagnose und behandlung von t-zelllymphomen
|
US20240166738A1
(en)
|
2021-03-23 |
2024-05-23 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
US20240174744A1
(en)
|
2021-03-29 |
2024-05-30 |
Scirhom Gmbh |
Methods of treatment using protein binders to irhom2 epitopes
|
US20240376171A1
(en)
|
2021-03-30 |
2024-11-14 |
Hoffmann-La Roche Inc. |
Protease-activated polypeptides
|
EP4313109A1
(de)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Apotransmission-polypeptide und deren verwendung bei der behandlung von krebs
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
US20240382592A1
(en)
|
2021-04-09 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022221409A1
(en)
|
2021-04-14 |
2022-10-20 |
Villaris Therapeutics, Inc. |
Anti-cd122 antibodies and uses thereof
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
EP4326871A1
(de)
|
2021-04-19 |
2024-02-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verwendung von splice-switching-oligonukleotiden zum exon-skipping-vermittelten knockdown von pim2
|
EP4326855A1
(de)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modifizierte säugerzellen
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
JP2024514281A
(ja)
|
2021-04-23 |
2024-04-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Nk細胞係合剤関連の有害作用の防止または軽減
|
TW202244059A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
IL306111A
(en)
|
2021-04-30 |
2023-11-01 |
Hoffmann La Roche |
Dosage for combined treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody and anti-CD79B antibody for antiretroviral drugs
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
TW202310876A
(zh)
|
2021-05-12 |
2023-03-16 |
美商建南德克公司 |
使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法
|
JP2024518545A
(ja)
|
2021-05-14 |
2024-05-01 |
ジェネンテック, インコーポレイテッド |
Trem2のアゴニスト
|
US20240261446A1
(en)
|
2021-05-17 |
2024-08-08 |
Université de Liège |
Anti-cd38 single domain antibodies in disease monitoring and treatment
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
EP4347657A1
(de)
|
2021-05-25 |
2024-04-10 |
Seagen Inc. |
Verfahren zur quantifizierung von anti-cd40-antikörpern
|
JP2024521783A
(ja)
|
2021-05-26 |
2024-06-04 |
ジェネンテック, インコーポレイテッド |
ヒトサイトメガロウイルスとの宿主細胞表面相互作用を調節するための方法
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
TW202306994A
(zh)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
抗ddr2抗體及其用途
|
CA3218692A1
(en)
|
2021-06-04 |
2022-12-08 |
Boehringer Ingelheim International Gmbh |
Anti-sirp-alpha antibodies
|
JP2024521579A
(ja)
|
2021-06-09 |
2024-06-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療における使用のための特定のbraf阻害剤(パラドックスブレーカー)とpd-1軸結合アンタゴニストとの組み合わせ
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
EP4355786A1
(de)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Bispezifische anti-mertk- und anti-pdl1-antikörper und verfahren zur verwendung davon
|
JP2024523033A
(ja)
|
2021-06-17 |
2024-06-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規の三重特異的結合分子
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
AR126220A1
(es)
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
BR112023023480A2
(pt)
|
2021-06-25 |
2024-01-30 |
Chugai Pharmaceutical Co Ltd |
Uso de anticorpo anti-ctla-4
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
BR112023026966A2
(pt)
|
2021-07-02 |
2024-03-12 |
Hoffmann La Roche |
Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
|
EP4367138A1
(de)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen
|
JP2024526315A
(ja)
|
2021-07-09 |
2024-07-17 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を製造するための製造方法
|
JP2024527586A
(ja)
|
2021-07-09 |
2024-07-25 |
ヤンセン バイオテツク,インコーポレーテツド |
抗-tnf抗体組成物を産生するための製造方法
|
EP4367130A1
(de)
|
2021-07-09 |
2024-05-15 |
Luxembourg Institute of Health (LIH) |
Dimere proteinkomplexe und verwendungen davon
|
EP4370550A1
(de)
|
2021-07-12 |
2024-05-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verwendung von il-36 inhibitoren zur behandlung des netherton syndroms
|
AU2022310847A1
(en)
|
2021-07-14 |
2024-01-25 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
EP4373576A1
(de)
|
2021-07-22 |
2024-05-29 |
Genentech, Inc. |
Auf das gehirn abzielende zusammensetzungen und verfahren zur verwendung davon
|
EP4377351A1
(de)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Verfahren und zusammensetzungen zur behandlung von krebs
|
WO2023010080A1
(en)
|
2021-07-30 |
2023-02-02 |
Seagen Inc. |
Treatment for cancer
|
US20240279336A1
(en)
|
2021-07-30 |
2024-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric proteins and methods of immunotherapy
|
JP2024528217A
(ja)
|
2021-08-03 |
2024-07-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗体および使用方法
|
EP4384553A1
(de)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosierung für antitryptase-antikörper
|
MX2024002295A
(es)
|
2021-08-27 |
2024-03-07 |
Genentech Inc |
Metodos para tratar las patologias de tau.
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
TW202313695A
(zh)
|
2021-09-15 |
2023-04-01 |
法商感應檢查療法公司 |
抗btn3a抗體在製備用於治療腫瘤的藥物的用途
|
WO2023053282A1
(ja)
|
2021-09-29 |
2023-04-06 |
中外製薬株式会社 |
がんの治療に用いるための細胞傷害誘導治療剤
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
EP4408478A1
(de)
|
2021-09-30 |
2024-08-07 |
Seagen Inc. |
B7-h4-antikörper-wirkstoff-konjugate zur behandlung von krebs
|
JP2024538677A
(ja)
|
2021-10-04 |
2024-10-23 |
タケダ ワクチン,インコーポレイテッド |
ノロウイルス反応性抗体を決定する方法
|
US20230190807A1
(en)
|
2021-10-06 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Tcr compounds, compositions, and methods of treating
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
IL311956A
(en)
|
2021-10-08 |
2024-06-01 |
Chugai Pharmaceutical Co Ltd |
Method for preparing prefilled syringe formulation
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
EP4429706A1
(de)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v-immunkonjugate zur behandlung von krebs
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
EP4423132A1
(de)
|
2021-10-27 |
2024-09-04 |
Imcheck Therapeutics |
Butyrophilin (btn) 3a aktivierende antikörper zur verwendung in verfahren zur behandlung von infektionskrankheiten
|
JP2024541946A
(ja)
|
2021-10-29 |
2024-11-13 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体を用いてクローン病を治療する方法
|
CN118201962A
(zh)
|
2021-11-01 |
2024-06-14 |
豪夫迈·罗氏有限公司 |
使用HLA-A2/WT1xCD3双特异性抗体和4-1BB(CD137)激动剂治疗癌症
|
EP4427044A1
(de)
|
2021-11-03 |
2024-09-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und zusammensetzungen zur behandlung von dreifach negativem brustkrebs (tnbc)
|
WO2023081925A1
(en)
|
2021-11-08 |
2023-05-11 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
MX2024005635A
(es)
|
2021-11-09 |
2024-07-29 |
Sensei Biotherapeutics Inc |
Anticuerpos anti-vista y usos de estos.
|
EP4430072A1
(de)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33-antikörper und verwendungen davon
|
EP4433501A1
(de)
|
2021-11-15 |
2024-09-25 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
MX2024005680A
(es)
|
2021-11-16 |
2024-05-30 |
Genentech Inc |
Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
EP4186529A1
(de)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
|
EP4437005A1
(de)
|
2021-11-25 |
2024-10-02 |
Veraxa Biotech GmbH |
Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
|
EP4441094A1
(de)
|
2021-11-29 |
2024-10-09 |
Ose Immunotherapeutics |
Spezifische antagonistische anti-sirpg-antikörper
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
JP2024546589A
(ja)
|
2021-12-14 |
2024-12-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hla-a2/mage-a4×cd3二重特異性抗体及び4-1bb(cd137)アゴニストを使用したがんの治療
|
US20250051472A1
(en)
|
2021-12-17 |
2025-02-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
AU2022408865A1
(en)
|
2021-12-17 |
2024-07-04 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
JP2025501522A
(ja)
|
2021-12-17 |
2025-01-22 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ox40抗体及び使用方法
|
US20250051755A1
(en)
|
2021-12-17 |
2025-02-13 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
US20250041261A1
(en)
|
2021-12-21 |
2025-02-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
US20250057968A1
(en)
|
2021-12-23 |
2025-02-20 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
|
EP4209508A1
(de)
|
2022-01-11 |
2023-07-12 |
Centre national de la recherche scientifique |
Nanokörpern für das deneddylierende enzym nedp1
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
US20250114472A1
(en)
|
2022-01-24 |
2025-04-10 |
Beijing Chempion Biotechnology Co., Ltd. |
Conjugate and use thereof
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
KR20240137090A
(ko)
|
2022-01-29 |
2024-09-19 |
카스젠 라이프 사이언스 씨오., 엘티디. |
Gprc5d 항체 및 그 용도
|
US20250067745A1
(en)
|
2022-01-31 |
2025-02-27 |
Institut National de la Santé et de la Recherche Médicale |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
EP4231017A1
(de)
|
2022-02-17 |
2023-08-23 |
Promise Proteomics |
Nachweis und quantifizierung von anti-arzneimittel-antikörpern und anti-selbst-antikörpern
|
EP4479415A1
(de)
|
2022-02-17 |
2024-12-25 |
ATB Therapeutics |
Rekombinantes immunotoxin, das ein ribosom inaktivierendes protein enthält
|
EP4489790A1
(de)
|
2022-03-10 |
2025-01-15 |
Vivasor, Inc. |
Antikörper-wirkstoff-konjugate und verwendungen davon
|
WO2023170247A1
(en)
|
2022-03-11 |
2023-09-14 |
Mablink Bioscience |
Antibody-drug conjugates and their uses
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
EP4499708A1
(de)
|
2022-03-25 |
2025-02-05 |
Shanghai Henlius Biotech, Inc. |
Anti-msln-antikörper und verfahren zur verwendung
|
EP4499229A1
(de)
|
2022-03-28 |
2025-02-05 |
F. Hoffmann-La Roche AG |
Interferon-gamma-varianten und antigenbindende moleküle damit
|
IL316022A
(en)
|
2022-03-30 |
2024-11-01 |
Janssen Biotech Inc |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
EP4504780A1
(de)
|
2022-04-01 |
2025-02-12 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-fcrh5/anti-cd3-antikörpern
|
EP4257609A1
(de)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
|
EP4508432A1
(de)
|
2022-04-11 |
2025-02-19 |
Institut National de la Santé et de la Recherche Médicale |
Verfahren zur diagnose und behandlung von t-zell-malignitäten
|
CN119013049A
(zh)
|
2022-04-12 |
2024-11-22 |
卫材R&D管理有限公司 |
基于艾日布林的抗体-药物缀合物及其使用方法
|
AU2023251832A1
(en)
|
2022-04-13 |
2024-10-17 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
CN119384432A
(zh)
|
2022-04-13 |
2025-01-28 |
基因泰克公司 |
治疗性蛋白质的药物组合物和使用方法
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
EP4514845A1
(de)
|
2022-04-29 |
2025-03-05 |
Broadwing Bio LLC |
Bispezifische antikörper und verfahren zur behandlung von augenerkrankungen
|
KR20250021400A
(ko)
|
2022-04-29 |
2025-02-12 |
브로드윙 바이오 엘엘씨 |
보체 인자 h 관련 4-특이적 항체 및 그의 용도
|
AU2023259251A1
(en)
|
2022-04-29 |
2024-11-14 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
CR20240526A
(es)
|
2022-05-03 |
2025-01-10 |
Genentech Inc |
Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
|
EP4522630A1
(de)
|
2022-05-10 |
2025-03-19 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1-fusionsproteine und verwendungen davon zur frachtlieferung in zielzellen
|
EP4522653A1
(de)
|
2022-05-11 |
2025-03-19 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-fcrh5/anti-cd3-antikörpern
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
CN119213034A
(zh)
|
2022-05-17 |
2024-12-27 |
苏州创胜医药集团有限公司 |
双功能蛋白质及其制剂和用途
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
US20230416412A1
(en)
|
2022-05-31 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
AU2023284422A1
(en)
|
2022-06-07 |
2024-12-19 |
Genentech, Inc. |
Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
CN117285644A
(zh)
|
2022-06-16 |
2023-12-26 |
清华大学 |
一种相变调节元件及其用途
|
CN117285643A
(zh)
|
2022-06-16 |
2023-12-26 |
清华大学 |
一种相变调节套件及其用途
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
EP4299124A1
(de)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2-nanokörper zur verwendung als biomolekültransporter
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024008274A1
(en)
|
2022-07-04 |
2024-01-11 |
Universiteit Antwerpen |
T regulatory cell modification
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
KR20250039373A
(ko)
|
2022-07-15 |
2025-03-20 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료를 위한 결합 분자
|
CN119604530A
(zh)
|
2022-07-19 |
2025-03-11 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
WO2024018003A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
|
AU2023312054A1
(en)
|
2022-07-22 |
2025-01-23 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024023246A1
(en)
|
2022-07-28 |
2024-02-01 |
Philogen S.P.A. |
Antibody binding to pd1
|
IL317876A
(en)
|
2022-07-29 |
2025-02-01 |
Alector Llc |
Transferrin receptor antigen binding domains and their uses
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
IL318860A
(en)
|
2022-08-08 |
2025-04-01 |
Atb Therapeutics |
Humanized antibodies against CD79B
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|
AU2023326586A1
(en)
|
2022-08-17 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Improved anti-albumin nanobodies and their uses
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
TW202421664A
(zh)
|
2022-10-07 |
2024-06-01 |
美商建南德克公司 |
用抗c—c模體趨化因子受體8(ccr8)抗體治療癌症之方法
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Gprc5d tcb及蛋白酶體抑制劑之組合療法
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Gprc5d tcb及imid之組合療法
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Gprc5d tcb及cd38抗體之組合療法
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
TW202434286A
(zh)
|
2022-11-08 |
2024-09-01 |
美商建南德克公司 |
治療兒童期發病的特發性腎病症候群之組成物及方法
|
WO2024102962A1
(en)
|
2022-11-10 |
2024-05-16 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024110898A1
(en)
|
2022-11-22 |
2024-05-30 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
TW202440623A
(zh)
|
2022-11-28 |
2024-10-16 |
美商艾洛基因醫療公司 |
靶向密連蛋白18﹒2之嵌合抗原受體及結合劑以及其用途
|
WO2024115935A1
(en)
|
2022-11-29 |
2024-06-06 |
Inserm |
Methods for the treatment of b-cell lymphoma using cd39 inhibitors
|
WO2024115349A1
(en)
|
2022-11-29 |
2024-06-06 |
F. Hoffmann-La Roche Ag |
Improved cancer immunotherapy
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
WO2024126685A1
(en)
|
2022-12-15 |
2024-06-20 |
Institut National de la Santé et de la Recherche Médicale |
Single-domain antibody targeting von wilebrand factor a3-domain
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|
WO2024133723A1
(en)
|
2022-12-22 |
2024-06-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
WO2024145551A1
(en)
|
2022-12-29 |
2024-07-04 |
Biotalys NV |
Agrochemical compositions
|
WO2024148232A2
(en)
|
2023-01-06 |
2024-07-11 |
Alector Llc |
Anti-il18 binding protein antibodies and methods of use thereof
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
WO2024149821A1
(en)
|
2023-01-13 |
2024-07-18 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
|
WO2024155807A1
(en)
|
2023-01-18 |
2024-07-25 |
Genentech, Inc. |
Multispecific antibodies and uses thereof
|
US20240262879A1
(en)
|
2023-01-20 |
2024-08-08 |
Boehringer Ingelheim International Gmbh |
IL-12 Fc FUSION PROTEINS
|
WO2024153789A1
(en)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
WO2024155901A2
(en)
|
2023-01-20 |
2024-07-25 |
Genentech, Inc. |
E3 ligase family functions and interactions
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
WO2024156881A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
CD8b-BINDING POLYPEPTIDES
|
WO2024156888A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
Cd163-binding conjugates
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
WO2024161038A1
(en)
|
2023-02-03 |
2024-08-08 |
Immusmol Sas |
Method of predicting success of a cancer therapy
|
WO2024175699A1
(en)
|
2023-02-23 |
2024-08-29 |
Imcheck Therapeutics |
Combination of btn3a activating antibody and immune checkpoint inhibitors
|
WO2024175760A1
(en)
|
2023-02-24 |
2024-08-29 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of endometriosis
|
WO2024182569A2
(en)
|
2023-02-28 |
2024-09-06 |
Eisai R&D Management Co., Ltd. |
Anti-psma antibodies, conjugates, and methods of use
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
WO2024188966A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist
|
WO2024200846A1
(en)
|
2023-03-30 |
2024-10-03 |
272BIO Limited |
Gnrh-binding polypeptides and uses thereof
|
WO2024208816A1
(en)
|
2023-04-03 |
2024-10-10 |
Vib Vzw |
Blood-brain barrier crossing antibodies
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024220546A2
(en)
|
2023-04-17 |
2024-10-24 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
WO2024223943A1
(en)
|
2023-04-27 |
2024-10-31 |
Imcheck Therapeutics |
Methods for treating multidrug resistant bacterial infections
|
WO2024227154A1
(en)
|
2023-04-28 |
2024-10-31 |
Broadwing Bio Llc |
Complement component 3 (c3)-specific antibodies and uses thereof
|
TW202448949A
(zh)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
WO2024231320A1
(en)
|
2023-05-08 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
WO2024231348A1
(en)
|
2023-05-11 |
2024-11-14 |
Vib Vzw |
Slc4a4/nbce1 inhibitors
|
WO2024238537A1
(en)
|
2023-05-16 |
2024-11-21 |
F. Hoffmann-La Roche Ag |
Pd-1 -regulated il-2 immunocytokine and uses thereof
|
WO2024236336A1
(en)
|
2023-05-17 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Lipc variant in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease
|
TW202449156A
(zh)
|
2023-05-18 |
2024-12-16 |
美商克雷德治療股份有限公司 |
抑制天然殺手細胞對細胞療法之細胞毒性
|
WO2024240635A1
(en)
|
2023-05-19 |
2024-11-28 |
Boehringer Ingelheim International Gmbh |
Uses of t cell engaging proteins in the treatment of cancer
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
TW202448933A
(zh)
|
2023-05-31 |
2024-12-16 |
美商建南德克公司 |
用抗轉化生長因子β3抗體治療TGFβ相關病症之方法
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
WO2024246086A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Immunostimulatory antigen binding molecules that specifically bind to bcma
|
WO2024251839A1
(en)
|
2023-06-05 |
2024-12-12 |
Pure Biologics Spólka Akcyjna |
Anti-garp antibodies and methods of use
|
WO2024251787A1
(en)
|
2023-06-05 |
2024-12-12 |
Pure Biologics Spólka Akcyjna |
Anti ror1 antibodies and method of use
|
EP4477236A1
(de)
|
2023-06-14 |
2024-12-18 |
Inatherys |
Kombinationstherapie zur behandlung eines tumors mit adc mit anti-cd71-antikörpern und bh3-mimetika
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
WO2024261013A1
(en)
|
2023-06-21 |
2024-12-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
WO2024263845A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Treatment of multiple myeloma
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
WO2025017186A1
(en)
|
2023-07-20 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Extracellular vesicles functionalized with a tethering system for cargo delivery
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
WO2025040598A2
(en)
|
2023-08-18 |
2025-02-27 |
Immatics Biotechnologies Gmbh |
Peptides displayed by mhc for use in immunotherapy against different types of cancer
|
EP4512243A1
(de)
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Bindungsmoleküle
|
WO2025040820A1
(en)
|
2023-08-23 |
2025-02-27 |
Granular Therapeutics Limited |
Anti-cd203c antibody conjugates and uses thereof
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
WO2025056655A1
(en)
|
2023-09-14 |
2025-03-20 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
WO2025056807A1
(en)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
WO2025068207A1
(en)
|
2023-09-25 |
2025-04-03 |
F. Hoffmann-La Roche Ag |
ANTIBODY THAT BINDS TO C3bBb
|
US12122842B1
(en)
|
2023-09-27 |
2024-10-22 |
R&D Systems, Inc. |
Human CD30-specific binding proteins and uses thereof
|